CA2641541A1 - Methods for inducing programmed cell death - Google Patents
Methods for inducing programmed cell death Download PDFInfo
- Publication number
- CA2641541A1 CA2641541A1 CA 2641541 CA2641541A CA2641541A1 CA 2641541 A1 CA2641541 A1 CA 2641541A1 CA 2641541 CA2641541 CA 2641541 CA 2641541 A CA2641541 A CA 2641541A CA 2641541 A1 CA2641541 A1 CA 2641541A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cell
- cells
- caspase
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000001939 inductive effect Effects 0.000 title claims abstract description 10
- 238000003782 apoptosis assay Methods 0.000 title description 8
- 230000005522 programmed cell death Effects 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 102000011727 Caspases Human genes 0.000 claims abstract description 57
- 108010076667 Caspases Proteins 0.000 claims abstract description 57
- 230000006907 apoptotic process Effects 0.000 claims abstract description 50
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 210
- 238000011282 treatment Methods 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 25
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 230000004663 cell proliferation Effects 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 230000001594 aberrant effect Effects 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 206010052779 Transplant rejections Diseases 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 11
- 208000037803 restenosis Diseases 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 208000037804 stenosis Diseases 0.000 claims description 6
- 230000036262 stenosis Effects 0.000 claims description 6
- KQCJZAUNKSGEFM-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C=C2OCC1C1=CC=C(O)C=C1 KQCJZAUNKSGEFM-UHFFFAOYSA-N 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- DFWZDHJUMZPOPU-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C(C)=C2OCC1C1=CC=C(O)C=C1 DFWZDHJUMZPOPU-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 230000030609 dephosphorylation Effects 0.000 claims description 3
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 229940125773 compound 10 Drugs 0.000 description 72
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 72
- 229940125904 compound 1 Drugs 0.000 description 59
- -1 isoflavonoid compounds Chemical class 0.000 description 44
- 150000002431 hydrogen Chemical class 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004072 Beclin-1 Human genes 0.000 description 18
- 108090000524 Beclin-1 Proteins 0.000 description 18
- 230000030833 cell death Effects 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 16
- 229920000858 Cyclodextrin Polymers 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 229960005277 gemcitabine Drugs 0.000 description 15
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 15
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000002438 mitochondrial effect Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 12
- 229930012538 Paclitaxel Natural products 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 210000003470 mitochondria Anatomy 0.000 description 12
- 229960001592 paclitaxel Drugs 0.000 description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000027829 mitochondrial depolarization Effects 0.000 description 11
- 102000004046 Caspase-2 Human genes 0.000 description 10
- 108090000552 Caspase-2 Proteins 0.000 description 10
- 102000004039 Caspase-9 Human genes 0.000 description 10
- 108090000566 Caspase-9 Proteins 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 206010028851 Necrosis Diseases 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000004900 autophagic degradation Effects 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000017074 necrotic cell death Effects 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 9
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 102100029855 Caspase-3 Human genes 0.000 description 8
- 102100021008 Endonuclease G, mitochondrial Human genes 0.000 description 8
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 108010047964 endonuclease G Proteins 0.000 description 8
- 229930013032 isoflavonoid Natural products 0.000 description 8
- 235000012891 isoflavonoids Nutrition 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000002424 anti-apoptotic effect Effects 0.000 description 6
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
- 102000055102 bcl-2-Associated X Human genes 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940123169 Caspase inhibitor Drugs 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 229960004562 carboplatin Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000016314 protein import into mitochondrial matrix Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 description 4
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 4
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000037059 G2/M phase arrest Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009789 autophagic cell death Effects 0.000 description 3
- 230000002886 autophagic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000006623 intrinsic pathway Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GZFUUMMGXBJXOJ-UHFFFAOYSA-N 3,4-bis(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)C2=CC=C(O)C(C)=C2OC1 GZFUUMMGXBJXOJ-UHFFFAOYSA-N 0.000 description 2
- LAIKGKBBBDSCNM-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C(C)=C2OCC1C1=CC=CC(O)=C1 LAIKGKBBBDSCNM-UHFFFAOYSA-N 0.000 description 2
- MFWFQBFPOAUFOC-UHFFFAOYSA-N 3-(3-methoxyphenyl)-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C(C)=C2OCC1C1=CC=CC(OC)=C1 MFWFQBFPOAUFOC-UHFFFAOYSA-N 0.000 description 2
- IVOGQYXSIZAOEL-UHFFFAOYSA-N 4-[7-hydroxy-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-3-yl]benzene-1,2-diol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C(C)=C2OCC1C1=CC=C(O)C(O)=C1 IVOGQYXSIZAOEL-UHFFFAOYSA-N 0.000 description 2
- MCRDYEOPNSHURJ-UHFFFAOYSA-N 4-[7-methoxy-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-3-yl]benzene-1,2-diol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(OC)C(C)=C2OCC1C1=CC=C(O)C(O)=C1 MCRDYEOPNSHURJ-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 101710204192 Mitochondrial nuclease Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940023476 agar Drugs 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004642 autophagic pathway Effects 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- 239000012822 autophagy inhibitor Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- SXMHBZFCCRGHQA-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(O)C=C2OCC1C1=CC=C(OC)C(OC)=C1 SXMHBZFCCRGHQA-UHFFFAOYSA-N 0.000 description 1
- NALARBCJDJUJAW-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-4-(4-methylphenyl)-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(C)=CC=C1C1C2=CC=C(O)C=C2OCC1C1=CC=C(O)C=C1 NALARBCJDJUJAW-UHFFFAOYSA-N 0.000 description 1
- FDMOAYIDJXKXDX-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-4-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1C(C=2C=CC=CC=2)C2=CC=C(O)C=C2OC1 FDMOAYIDJXKXDX-UHFFFAOYSA-N 0.000 description 1
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical class OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- ZVKVETUIDLLDCZ-UHFFFAOYSA-N 4-[7-methoxy-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-3-yl]phenol Chemical compound C1=CC(OC)=CC=C1C1C2=CC=C(OC)C(C)=C2OCC1C1=CC=C(O)C=C1 ZVKVETUIDLLDCZ-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- RMZDIUZQIPQODD-UHFFFAOYSA-N 7-methoxy-3,4-bis(4-methoxyphenyl)-3,4-dihydro-2h-chromene Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)C2=CC=C(OC)C=C2OC1 RMZDIUZQIPQODD-UHFFFAOYSA-N 0.000 description 1
- RBKBOQGLIKPPJE-UHFFFAOYSA-N 7-methoxy-3,4-bis(4-methoxyphenyl)-8-methyl-3,4-dihydro-2h-chromene Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)C2=CC=C(OC)C(C)=C2OC1 RBKBOQGLIKPPJE-UHFFFAOYSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000005711 Keratin-7 Human genes 0.000 description 1
- 108010070507 Keratin-7 Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101100275485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-4 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101710195703 Oxygen-dependent coproporphyrinogen-III oxidase Proteins 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- 101710200437 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005033 autophagosome formation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004924 electrostatic deposition Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical class C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 125000004388 isoflavanoid group Chemical class 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 238000007649 pad printing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001713 poly(ethylene-co-vinyl alcohol) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to methods for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I
as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
Description
Methods for Inducing Programmed Cell Death Field of the Invention The present invention relates generally to methods for inducing or promoting caspase-independent apoptosis and for inhibiting mTOR activity. The invention also relates to the treatment of diseases and conditions associated with aberrant/unwanted cell growth and/or proliferation.
Background of the Invention Programmed cell death is an evolutionary conserved pathway, the activation of which leads to an energy-dependent cell suicide mechanism. Two forms of programmed cell death are generally described in the literature, apoptosis or caspase-dependent cell death, and caspase-independent cell death. Caspase-dependent apoptosis is the better characterized pathway of the two types of programmed cell death such that the terms programmed cell death and apoptosis are typically used interchangeably. Caspase-mediated apoptosis involves the sequential activation of a group of proteases, the caspases, and can be activated either by ligation of death receptors like Fas and TNFR (extrinsic pathway), or by mitochondrial depolarization (intrinsic pathway). The Bc12 family of proteins, which has both pro-apoptotic (Bak, Bax, etc.) and anti-apoptotic members (Bc12, BclX), controls mitochondrial integrity and the decision to engage the intrinsic pathway depends on the ratio of the pro-and anti-apoptotic members in the outer mitochondrial membrane.
Caspase-independent cell death encompasses events that occur when cells die in the absence of caspase activation. Autophagy is the most characterized caspase-independent programmed cell death pathway and is often called Type II programmed cell death. It involves the controlled formation of autophagosomes, double-membrane cytoplasmic vesicles, which can fuse with lysosomes thus leading to the digestion of molecules within the autophagosome.
Autophagy is controlled by the Akt-mTOR pathway and involves key proteins such as Beclin-1 and Class III P13 kinase. It is a pathway activated to promote cell survival, but due to the inherent mechanisms invoked can also lead to cell death. Other pathways for caspase-independent cell death, including caspase-independent apoptosis are reviewed in Hail et al, 2006.
Numerous studies have shown that most chemotherapy agents induce cell death by activating the apoptotic pathway and that resistance to apoptosis due to high intracellular levels of anti-apoptotic blockers like XIAP is a major cause of chemo-resistance. Indeed, molecular or drug targeting of apoptotic blockers like XIAP results in the reversal of chemo-resistance (see, for example, Alvero et al, 2006; Kluger et al, 2007). Aberrant cell growth and/or proliferation is also associated with a wide variety of disease conditions and there is increasing interest in the therapeutic application of apoptosis inducers.
As herein described, the present inventors have identified a class of isoflavonoid compounds which induce caspase-independent non-autophagic programmed cell death in human cells, thereby opening up a range of novel therapeutic avenues.
Summary of the Invention According to a first aspect there is provided a method for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) Rg RIo I / Rs R5 \ ~ R6 wherein Ri is hydrogen, hydroxy, alkyl, alkoxy, halo or OC(O)R7, R2 and R3 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, halo or OC(O)R7, R4, R5 and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, amino, C14-alkylamino or di(Cl-4-alkyl)amino, OC(O)R7 or ORB, R7 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl or amino, and Ra is aryl or arylalkyl, Rs and Rio are independently hydrogen, hydroxy, alkyl, alkoxy or halo, and the drawing "_" represents a single bond or a double bond, or a pharmaceutically acceptable salt or derivative thereof.
In one embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
Me HO O
I \
OH
OMe In an alternative embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
HO O
OH
OMe Exposure of the cell to the compound may occur in v'itro, ex vivo or in vivo.
In a particular embodiment the cell is not a cancer cell. By way of example the cell may be a myocardial cell or immune cell. The immune cell may be a proliferating T cell.
According to a second aspect there is provided a method for inhibiting mTOR
activity in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) as described herein.
Typically the inhibition of mTOR activity comprises dephosphorylation of mTOR.
According to a third aspect there is provided a method for the treatment or prevention of a disease or condition, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof, optionally in association with one or more pharmaceutically acceptable diluents, adjuvants and/or excipients, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
According to a fourth aspect there is provided a method for the treatment or prevention of a disease or condition, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof, optionally in association with one or more pharmaceutically acceptable diluents, adjuvants and/or excipients, wherein the compound inhibits mTOR activity in at least one cell of the subject.
In a particular embodiment in accordance with the third or fourth aspect the cell is not a cancer cell.
By way of example the cell may be a myocardial cell or an immune cell.
Typically in accordance with the third or fourth aspect the disease or condition is associated with aberrant or otherwise unwanted cell growth or proliferation. In an embodiment, the disease or condition may be selected from stenosis or restenosis, transplant rejection or rheumatoid arthritis.
Where the cell proliferation is T cell proliferation, the disease or condition may be selected from T
cell leukemias, autoimmune diseases, and transplant or graft rejections such as graft versus host disease. Autoimmune diseases include, but are not limited to, cirrhosis, psoriasis, lupus, rheumatoid arthritis, Addison's disease, infectious mononucleosis, S6zary's syndrome and Epstein-Barr virus infection.
For the treatment of stenosis or restenosis the compound or a composition comprising the compound may be coated onto or otherwise incorporated into a stent for introduction into a coronary artery. The stent may be such that the compound or composition is eluted from the stent over a period of time so as to achieve the desired outcome.
In one embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
Background of the Invention Programmed cell death is an evolutionary conserved pathway, the activation of which leads to an energy-dependent cell suicide mechanism. Two forms of programmed cell death are generally described in the literature, apoptosis or caspase-dependent cell death, and caspase-independent cell death. Caspase-dependent apoptosis is the better characterized pathway of the two types of programmed cell death such that the terms programmed cell death and apoptosis are typically used interchangeably. Caspase-mediated apoptosis involves the sequential activation of a group of proteases, the caspases, and can be activated either by ligation of death receptors like Fas and TNFR (extrinsic pathway), or by mitochondrial depolarization (intrinsic pathway). The Bc12 family of proteins, which has both pro-apoptotic (Bak, Bax, etc.) and anti-apoptotic members (Bc12, BclX), controls mitochondrial integrity and the decision to engage the intrinsic pathway depends on the ratio of the pro-and anti-apoptotic members in the outer mitochondrial membrane.
Caspase-independent cell death encompasses events that occur when cells die in the absence of caspase activation. Autophagy is the most characterized caspase-independent programmed cell death pathway and is often called Type II programmed cell death. It involves the controlled formation of autophagosomes, double-membrane cytoplasmic vesicles, which can fuse with lysosomes thus leading to the digestion of molecules within the autophagosome.
Autophagy is controlled by the Akt-mTOR pathway and involves key proteins such as Beclin-1 and Class III P13 kinase. It is a pathway activated to promote cell survival, but due to the inherent mechanisms invoked can also lead to cell death. Other pathways for caspase-independent cell death, including caspase-independent apoptosis are reviewed in Hail et al, 2006.
Numerous studies have shown that most chemotherapy agents induce cell death by activating the apoptotic pathway and that resistance to apoptosis due to high intracellular levels of anti-apoptotic blockers like XIAP is a major cause of chemo-resistance. Indeed, molecular or drug targeting of apoptotic blockers like XIAP results in the reversal of chemo-resistance (see, for example, Alvero et al, 2006; Kluger et al, 2007). Aberrant cell growth and/or proliferation is also associated with a wide variety of disease conditions and there is increasing interest in the therapeutic application of apoptosis inducers.
As herein described, the present inventors have identified a class of isoflavonoid compounds which induce caspase-independent non-autophagic programmed cell death in human cells, thereby opening up a range of novel therapeutic avenues.
Summary of the Invention According to a first aspect there is provided a method for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) Rg RIo I / Rs R5 \ ~ R6 wherein Ri is hydrogen, hydroxy, alkyl, alkoxy, halo or OC(O)R7, R2 and R3 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, halo or OC(O)R7, R4, R5 and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, amino, C14-alkylamino or di(Cl-4-alkyl)amino, OC(O)R7 or ORB, R7 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl or amino, and Ra is aryl or arylalkyl, Rs and Rio are independently hydrogen, hydroxy, alkyl, alkoxy or halo, and the drawing "_" represents a single bond or a double bond, or a pharmaceutically acceptable salt or derivative thereof.
In one embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
Me HO O
I \
OH
OMe In an alternative embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
HO O
OH
OMe Exposure of the cell to the compound may occur in v'itro, ex vivo or in vivo.
In a particular embodiment the cell is not a cancer cell. By way of example the cell may be a myocardial cell or immune cell. The immune cell may be a proliferating T cell.
According to a second aspect there is provided a method for inhibiting mTOR
activity in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) as described herein.
Typically the inhibition of mTOR activity comprises dephosphorylation of mTOR.
According to a third aspect there is provided a method for the treatment or prevention of a disease or condition, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof, optionally in association with one or more pharmaceutically acceptable diluents, adjuvants and/or excipients, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
According to a fourth aspect there is provided a method for the treatment or prevention of a disease or condition, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof, optionally in association with one or more pharmaceutically acceptable diluents, adjuvants and/or excipients, wherein the compound inhibits mTOR activity in at least one cell of the subject.
In a particular embodiment in accordance with the third or fourth aspect the cell is not a cancer cell.
By way of example the cell may be a myocardial cell or an immune cell.
Typically in accordance with the third or fourth aspect the disease or condition is associated with aberrant or otherwise unwanted cell growth or proliferation. In an embodiment, the disease or condition may be selected from stenosis or restenosis, transplant rejection or rheumatoid arthritis.
Where the cell proliferation is T cell proliferation, the disease or condition may be selected from T
cell leukemias, autoimmune diseases, and transplant or graft rejections such as graft versus host disease. Autoimmune diseases include, but are not limited to, cirrhosis, psoriasis, lupus, rheumatoid arthritis, Addison's disease, infectious mononucleosis, S6zary's syndrome and Epstein-Barr virus infection.
For the treatment of stenosis or restenosis the compound or a composition comprising the compound may be coated onto or otherwise incorporated into a stent for introduction into a coronary artery. The stent may be such that the compound or composition is eluted from the stent over a period of time so as to achieve the desired outcome.
In one embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
Me HO O
OH
OMe In an altemative embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
HO O
OH
OMe According to a fifth aspect there is provided an agent for the treatment or prevention of a disease or condition associated with aberrant or otherwise unwanted cell growth and/or proliferation, the agent comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof.
According to a sixth aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for inducing or promoting caspase-independent apoptosis in a cell.
According to a seventh aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for inhibiting mTOR activity in a cell.
According to an eighth aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for treating or preventing a disease or condition, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
OH
OMe In an altemative embodiment, the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
HO O
OH
OMe According to a fifth aspect there is provided an agent for the treatment or prevention of a disease or condition associated with aberrant or otherwise unwanted cell growth and/or proliferation, the agent comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof.
According to a sixth aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for inducing or promoting caspase-independent apoptosis in a cell.
According to a seventh aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for inhibiting mTOR activity in a cell.
According to an eighth aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for treating or preventing a disease or condition, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
According to a ninth aspect there is provided the use of a compound of formula (I) as described herein for the manufacture of a medicament for treating or preventing a disease or condition, wherein the compound inhibits mTOR activity in at least one cell of the subject.
According to a tenth aspect there is provided an implantable medical device for delivering at least one active agent to a cell or tissue in a subject, wherein the at least one active agent comprises a compound of formula (I) as described herein.
Typically the compound is coated onto or otherwise incorporated into the device for administration of the compound to the cell or tissue. Optionally, the device also includes one or more additional active agents.
In an embodiment, the implantable medical device is a drug-eluting stent.
Typically in accordance with the above aspects and embodiments the subject is human. In other embodiments, the subject may be selected from the group consisting of, but not limited to: primate, ovine, bovine, canine, feline, porcine, equine and murine.
Brief Description of the Drawings The present invention will now be described, by way of non-limiting example only, with reference to the accompanying drawings.
Figure 1. (A) EOC cells were treated with increasing concentrations of Compound 1 for 24h and cell viability determined as described herein. Results shown are representative of three independent experiments. (B) No-treatment control cells, and cells treated with Compound 1 (10 g/ml) for 24h, were stained with Hoechst and PI and analyzed by flow cytometry. (C) Caspase activity was measured in cell lysates obtained from cells treated with increasing concentrations of Compound 1 or 2pM Paclitaxel for 24h.
Figure 2. EOC cells were treated with 10 g/mI Compound 1 for the indicated time and whole cells lysates were analyzed by western blot for XIAP (A) and phospho-Akt (p-Akt) (B). f3-actin and Akt blots demonstrate even loading. (C) Cells were treated with increasing concentrations of Compound 1 for 24h in the presence or absence of Z-VAD-FMK (20 pM) or 3-MA (10 pM).
These data are representative of those results obtained from all EOC cell lines analyzed.
According to a tenth aspect there is provided an implantable medical device for delivering at least one active agent to a cell or tissue in a subject, wherein the at least one active agent comprises a compound of formula (I) as described herein.
Typically the compound is coated onto or otherwise incorporated into the device for administration of the compound to the cell or tissue. Optionally, the device also includes one or more additional active agents.
In an embodiment, the implantable medical device is a drug-eluting stent.
Typically in accordance with the above aspects and embodiments the subject is human. In other embodiments, the subject may be selected from the group consisting of, but not limited to: primate, ovine, bovine, canine, feline, porcine, equine and murine.
Brief Description of the Drawings The present invention will now be described, by way of non-limiting example only, with reference to the accompanying drawings.
Figure 1. (A) EOC cells were treated with increasing concentrations of Compound 1 for 24h and cell viability determined as described herein. Results shown are representative of three independent experiments. (B) No-treatment control cells, and cells treated with Compound 1 (10 g/ml) for 24h, were stained with Hoechst and PI and analyzed by flow cytometry. (C) Caspase activity was measured in cell lysates obtained from cells treated with increasing concentrations of Compound 1 or 2pM Paclitaxel for 24h.
Figure 2. EOC cells were treated with 10 g/mI Compound 1 for the indicated time and whole cells lysates were analyzed by western blot for XIAP (A) and phospho-Akt (p-Akt) (B). f3-actin and Akt blots demonstrate even loading. (C) Cells were treated with increasing concentrations of Compound 1 for 24h in the presence or absence of Z-VAD-FMK (20 pM) or 3-MA (10 pM).
These data are representative of those results obtained from all EOC cell lines analyzed.
Figure 3. EOC cells were treated with 10 g/ml Compound 1 for the indicated time and whole cells lysates were analyzed by westem blot for (A) phospho-mTOR and pS6k; (B) LC3-ll; and (C) levels of 8 phospho-proteins as described herein. P-actin, mTOR, and S6k blots demonstrate even loading.
Figure 4. A confocal microscope image of EOC cells either unstimulated (A) or treated with 10 g/ml Compound I for 2h (B). Note the presence of intra-cellular vacoules in B but not in A (red arrows).
Fluoresence microscope images of cells stained with JC-1; unstimulated (C) or treated with 10 Ng/ml Compound 1 for 2h (D). Rounded arrow points to punctuate red staining in unstimulated cells;
diamond-ending arrow points to a cell with some mitochondrial depolarization;
and arrowhead points to a cell with bright green fluorescence suggesting most mitochondria have depolarized.
Figure 5. EOC cells were treated with 10 pg/mI Compound 1 for 1 h (A) and 4h (B), stained with JC-I dye, and analyzed by flow cytometry. Results are from a representative cell line. Similar results were obtained with other lines.
Figure 6. (A) Westem blot analysis of cell lysates and mitochondrial fractions prepared from EOC
cells treated with 10 Ng/mI Compound 1. Total cell lysates were analyzed for full-length Bid and mitochondrial fractions were analyzed for Beclin-1 and Bax. 0-actin and VDAC
are shown as loading controls. (B) Western blot analysis of anti-Beclin immunoprecipitates, derived from mitochondrial fractions of Compound 1 (10 Ng/mi,1 h) treated EOC cells, probed with anti-Bcl-2 and anti-Bak.
Figure 7. EOC cells were treated with Compound 1 (10 pg/ml) for the indicated time and nuclear fractions prepared as described herein. Levels of AIF and EndoG were determined by western blot analyses. Topoisomerase I(Topo-I) is shown as loading control.
Figure 8. EOC tumors were established s.c. in NCR nude mice and treatments were given as described herein. Tumor size was determined by caliper measurements. (A) EOC
tumor proliferation kinetics and (B) terminal tumor mass from mice dosed with vehicle control, paclitaxel, carboplatin, or Compound 1; (C) Excised tumors from representative mice dosed with either vehicle or Compound 1 (50 or 100 444 mg/kg); (D) Tumors from representative mice were lysed and analyzed by western blot analysis for phospho-S6 kinase (p-S6K) and total S6 kinase (S6K). (E) Paraffin-embedded sections of mouse tumors were analyzed for the localization of Endo by IHC. * p =_0.02, relative to vehicle.
Figure 4. A confocal microscope image of EOC cells either unstimulated (A) or treated with 10 g/ml Compound I for 2h (B). Note the presence of intra-cellular vacoules in B but not in A (red arrows).
Fluoresence microscope images of cells stained with JC-1; unstimulated (C) or treated with 10 Ng/ml Compound 1 for 2h (D). Rounded arrow points to punctuate red staining in unstimulated cells;
diamond-ending arrow points to a cell with some mitochondrial depolarization;
and arrowhead points to a cell with bright green fluorescence suggesting most mitochondria have depolarized.
Figure 5. EOC cells were treated with 10 pg/mI Compound 1 for 1 h (A) and 4h (B), stained with JC-I dye, and analyzed by flow cytometry. Results are from a representative cell line. Similar results were obtained with other lines.
Figure 6. (A) Westem blot analysis of cell lysates and mitochondrial fractions prepared from EOC
cells treated with 10 Ng/mI Compound 1. Total cell lysates were analyzed for full-length Bid and mitochondrial fractions were analyzed for Beclin-1 and Bax. 0-actin and VDAC
are shown as loading controls. (B) Western blot analysis of anti-Beclin immunoprecipitates, derived from mitochondrial fractions of Compound 1 (10 Ng/mi,1 h) treated EOC cells, probed with anti-Bcl-2 and anti-Bak.
Figure 7. EOC cells were treated with Compound 1 (10 pg/ml) for the indicated time and nuclear fractions prepared as described herein. Levels of AIF and EndoG were determined by western blot analyses. Topoisomerase I(Topo-I) is shown as loading control.
Figure 8. EOC tumors were established s.c. in NCR nude mice and treatments were given as described herein. Tumor size was determined by caliper measurements. (A) EOC
tumor proliferation kinetics and (B) terminal tumor mass from mice dosed with vehicle control, paclitaxel, carboplatin, or Compound 1; (C) Excised tumors from representative mice dosed with either vehicle or Compound 1 (50 or 100 444 mg/kg); (D) Tumors from representative mice were lysed and analyzed by western blot analysis for phospho-S6 kinase (p-S6K) and total S6 kinase (S6K). (E) Paraffin-embedded sections of mouse tumors were analyzed for the localization of Endo by IHC. * p =_0.02, relative to vehicle.
Figure 9. Effects of Caspase Inhibitor I (z-VAD-fmk) on Compound 10-induced apoptosis and necrosis in pancreatic adenocarcinoma cells as measure by FACS analysis. A.
HPAC, B. MIAPaCa-2. Cells were pre-incubated with 10 pM z-VAD-fmk for 1 h prior to the addition of 10 pM Compound 10. After 42-46h the cells were harvested and assayed for apoptosis by FACS
analysis. As positive caspase-dependent controls HPAC cells were challenged with a Fas-activating antibody (CH-1 1, Upstate) while MIAPaCa-2 cells were exposed to 50 ng/mL TRAIL (Alexis). In each spectrum, 10,000 gated events were recorded and analysed. All experiments were done in triplicate, error bars represent one standard deviation.
Figure 10. In Situ caspase activity in pancreatic cancer cells as measured by FACS analysis. (A) A
histogram of Caspases-2, -3 and -9 activity in Compound 10 treated (10 pM, 24 hr) and untreated MIAPaCa-2 cells; (B) histogram of caspase-2, -3 and -9 activity in Compound 10 treated (10 pM, 24 hr) and untreated HPAC cells; (C) A histogram of caspase-2 and -3 and -9 activity in Compound 10 treated (10pM, 24 hr) and untreated PANC-1 cells. All experiments were done in triplicate, error bars represent one standard deviation.
Figure 11. Western blot analysis of key regulatory proteins integral to apoptosis, and p21 and p53.
(A) Western blot analysis of caspase 2, caspase 9, XIAP, Bcl-2, Bid in MIAPaCa-2 cells and Akt in MIAPaCa-2 and HPAC cells. (B) Western blot analysis p2land p53 expression in MIAPaCa-2 and HPAC cells. In both data sets cells were treated with 10 pM Compound 10 for 0, 4, 8, 16, 24 & 48 hrs. Cells were lysed, preparations centrifuged, and lysates collected.
Respective cell lysate (25 pg) samples from each time point were separated by SDS-PAGE, transferred to PVDF membranes and probed with antibodies specific to the target antigen. Protein loading was standardised to GAPDH and the GAPDH data shown is representative of replicate studies (RDI).
(C) Westem blot analysis of cytochrome c release from PANC-1 cells treated with Compound 10 (5 and 10Ng/mI) for 48 hrs. A parallel experiment was performed where the cytoplasmic and mitochondrial fractions were separated before Western blot analyses. Cox-4 was included to show the integrity of the cytoplasmic and mitochondrial preparations and protein loading was standardised to R-actin.
Figure 12. Effect of Compound 10 on mitochondrial membrane potential of HPAC
and MIAPaCa-2 cells. MIAPaCa-2 cells were exposed to. 0 pM (A), or 100 pM (B) Compound 10 for 48 hrs.
Aggregated JC-1 red fluorescence from intact, polarized mitochondria is displayed on the Y axis while monomeric JC-1 green fluorescence from apoptotic cells with depolarized mitochondria is displayed on the X axis. The upper left quadrant is defined as polarized cells. The sum of the upper right and lower right quadrants are defined as depolarized cells. In each spectrum, 10,000 gated events were recorded and analysed. Mitochondrial membrane potential was measured in HPAC (C) or MIAPaCa-2 (D) cells over increasing concentrations of Compound 10. All experiments were done in triplicate.
Figure 13. Effect of Compound 10 on cell cycle progression in MIAPaCa-2, HPAC
and PANC-1 cells. (A) Representative FACS histograms of untreated and Compound 10 treated (10pM, 4hr and 24 hr) MIAPaCa-2 cells, HPAC cells and PANC-1 cells. Gates: M1 = sub-Go/Gi, M2 = Go/Gi, M3 =
S, M4 = G2/M and M5 = polyploidy cells. In each spectrum, 10,000 gated events were recorded and analysed. AII experiments were done in triplicate; (B) Combined plots of cell cycle distribution. Cells were exposed to 10 pM Compound 10 for 0, 4, 24 and 48 hrs. Cells were fixed in ethanol, stained with propidium iodide and analysed by FACS analysis. All experiments were done in triplicate, error bars represent one standard deviation.
Detailed Description of the Invention Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
As used herein the terms "treating", "treatment", "preventing" and "prevention" refer to any and all uses which remedy a condition or symptoms, prevent the establishment of a condition or disease, or otherwise prevent, hinder, retard, or reverse the progression of a condition or disease or other undesirable symptoms in any way whatsoever. Thus the terms "treating" and "preventing" and the like are to be considered in their broadest context. For example, treatment does not necessarily imply that a patient is treated until total recovery.
As used herein the terms "effective amount" and "effective dose" include within their meaning a non-toxic but sufficient amount or dose of an agent or compound to provide the desired effect. The exact amount or dose required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact "effective amount" or "effective dose".
However, for any given case, an appropriate "effective amount" or "effective dose" may be determined by one of ordinary skill in the art using only routine experimentation.
The term "pharmaceutically acceptable salt" refers to an organic or inorganic moiety that carries a charge and that can be administered in association with a pharmaceutical agent, for example, as a counter-cation or counter-anion in a salt. Pharmaceutically acceptable cations are known to those of skilled in the art, and include but are not limited to sodium, potassium, calcium, zinc and quaternary amine. Pharmaceutically acceptable anions are known to those of skill in the art, and inciude but are not limited to chloride, acetate, citrate, bicarbonate and carbonate.
The term "pharmaceutically acceptable derivative" refers to a derivative of the active compound that upon administration to the recipient, is capable of providing directly or indirectly, the parent compound or metabolite, or that exhibits activity itself. Prodrugs are included within the scope of the present invention.
Compounds 1 and 10, exemplified herein, are members of a phenyl-substituted isoflavan family of compounds with anti-proliferative activity against a range of cancer cell lines. The present application describes the activation in human cells by compounds of this family of a caspase-independent non-autophagic cell death pathway. At least in the case of Compound 1, this involves the dephosphorylation of mTOR. As exemplified herein, it is demonstrated that paclitaxel-resistant cell lines undergo caspase-independent cell death in the presence of Compound 1, characterized by down-regulation of p-mTOR, Beclin-1 mitochondrial translocation, nuclear translocation of the nuclease EndoG, and DNA fragmentation. Cell death is not autophagic, proceeding in the presence of apoptotic inducers, and hence is termed herein "caspase-independent apoptosis". Similarly, Compound 10 is demonstrated to induce cell cycle arrest leading to apoptosis in a range of cell lines.
That Compound 10-induced apoptosis proceeds in the presence of a pan-acting caspase inhibitor indicates that both caspase-mediated and caspase-independent pathways of apoptosis are induced.
In one aspect, the present invention provides a method for inducing or promoting apoptosis in a cell, the method comprising exposing to the cell and effective amount of a compound of formula I.
HPAC, B. MIAPaCa-2. Cells were pre-incubated with 10 pM z-VAD-fmk for 1 h prior to the addition of 10 pM Compound 10. After 42-46h the cells were harvested and assayed for apoptosis by FACS
analysis. As positive caspase-dependent controls HPAC cells were challenged with a Fas-activating antibody (CH-1 1, Upstate) while MIAPaCa-2 cells were exposed to 50 ng/mL TRAIL (Alexis). In each spectrum, 10,000 gated events were recorded and analysed. All experiments were done in triplicate, error bars represent one standard deviation.
Figure 10. In Situ caspase activity in pancreatic cancer cells as measured by FACS analysis. (A) A
histogram of Caspases-2, -3 and -9 activity in Compound 10 treated (10 pM, 24 hr) and untreated MIAPaCa-2 cells; (B) histogram of caspase-2, -3 and -9 activity in Compound 10 treated (10 pM, 24 hr) and untreated HPAC cells; (C) A histogram of caspase-2 and -3 and -9 activity in Compound 10 treated (10pM, 24 hr) and untreated PANC-1 cells. All experiments were done in triplicate, error bars represent one standard deviation.
Figure 11. Western blot analysis of key regulatory proteins integral to apoptosis, and p21 and p53.
(A) Western blot analysis of caspase 2, caspase 9, XIAP, Bcl-2, Bid in MIAPaCa-2 cells and Akt in MIAPaCa-2 and HPAC cells. (B) Western blot analysis p2land p53 expression in MIAPaCa-2 and HPAC cells. In both data sets cells were treated with 10 pM Compound 10 for 0, 4, 8, 16, 24 & 48 hrs. Cells were lysed, preparations centrifuged, and lysates collected.
Respective cell lysate (25 pg) samples from each time point were separated by SDS-PAGE, transferred to PVDF membranes and probed with antibodies specific to the target antigen. Protein loading was standardised to GAPDH and the GAPDH data shown is representative of replicate studies (RDI).
(C) Westem blot analysis of cytochrome c release from PANC-1 cells treated with Compound 10 (5 and 10Ng/mI) for 48 hrs. A parallel experiment was performed where the cytoplasmic and mitochondrial fractions were separated before Western blot analyses. Cox-4 was included to show the integrity of the cytoplasmic and mitochondrial preparations and protein loading was standardised to R-actin.
Figure 12. Effect of Compound 10 on mitochondrial membrane potential of HPAC
and MIAPaCa-2 cells. MIAPaCa-2 cells were exposed to. 0 pM (A), or 100 pM (B) Compound 10 for 48 hrs.
Aggregated JC-1 red fluorescence from intact, polarized mitochondria is displayed on the Y axis while monomeric JC-1 green fluorescence from apoptotic cells with depolarized mitochondria is displayed on the X axis. The upper left quadrant is defined as polarized cells. The sum of the upper right and lower right quadrants are defined as depolarized cells. In each spectrum, 10,000 gated events were recorded and analysed. Mitochondrial membrane potential was measured in HPAC (C) or MIAPaCa-2 (D) cells over increasing concentrations of Compound 10. All experiments were done in triplicate.
Figure 13. Effect of Compound 10 on cell cycle progression in MIAPaCa-2, HPAC
and PANC-1 cells. (A) Representative FACS histograms of untreated and Compound 10 treated (10pM, 4hr and 24 hr) MIAPaCa-2 cells, HPAC cells and PANC-1 cells. Gates: M1 = sub-Go/Gi, M2 = Go/Gi, M3 =
S, M4 = G2/M and M5 = polyploidy cells. In each spectrum, 10,000 gated events were recorded and analysed. AII experiments were done in triplicate; (B) Combined plots of cell cycle distribution. Cells were exposed to 10 pM Compound 10 for 0, 4, 24 and 48 hrs. Cells were fixed in ethanol, stained with propidium iodide and analysed by FACS analysis. All experiments were done in triplicate, error bars represent one standard deviation.
Detailed Description of the Invention Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
As used herein the terms "treating", "treatment", "preventing" and "prevention" refer to any and all uses which remedy a condition or symptoms, prevent the establishment of a condition or disease, or otherwise prevent, hinder, retard, or reverse the progression of a condition or disease or other undesirable symptoms in any way whatsoever. Thus the terms "treating" and "preventing" and the like are to be considered in their broadest context. For example, treatment does not necessarily imply that a patient is treated until total recovery.
As used herein the terms "effective amount" and "effective dose" include within their meaning a non-toxic but sufficient amount or dose of an agent or compound to provide the desired effect. The exact amount or dose required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact "effective amount" or "effective dose".
However, for any given case, an appropriate "effective amount" or "effective dose" may be determined by one of ordinary skill in the art using only routine experimentation.
The term "pharmaceutically acceptable salt" refers to an organic or inorganic moiety that carries a charge and that can be administered in association with a pharmaceutical agent, for example, as a counter-cation or counter-anion in a salt. Pharmaceutically acceptable cations are known to those of skilled in the art, and include but are not limited to sodium, potassium, calcium, zinc and quaternary amine. Pharmaceutically acceptable anions are known to those of skill in the art, and inciude but are not limited to chloride, acetate, citrate, bicarbonate and carbonate.
The term "pharmaceutically acceptable derivative" refers to a derivative of the active compound that upon administration to the recipient, is capable of providing directly or indirectly, the parent compound or metabolite, or that exhibits activity itself. Prodrugs are included within the scope of the present invention.
Compounds 1 and 10, exemplified herein, are members of a phenyl-substituted isoflavan family of compounds with anti-proliferative activity against a range of cancer cell lines. The present application describes the activation in human cells by compounds of this family of a caspase-independent non-autophagic cell death pathway. At least in the case of Compound 1, this involves the dephosphorylation of mTOR. As exemplified herein, it is demonstrated that paclitaxel-resistant cell lines undergo caspase-independent cell death in the presence of Compound 1, characterized by down-regulation of p-mTOR, Beclin-1 mitochondrial translocation, nuclear translocation of the nuclease EndoG, and DNA fragmentation. Cell death is not autophagic, proceeding in the presence of apoptotic inducers, and hence is termed herein "caspase-independent apoptosis". Similarly, Compound 10 is demonstrated to induce cell cycle arrest leading to apoptosis in a range of cell lines.
That Compound 10-induced apoptosis proceeds in the presence of a pan-acting caspase inhibitor indicates that both caspase-mediated and caspase-independent pathways of apoptosis are induced.
In one aspect, the present invention provides a method for inducing or promoting apoptosis in a cell, the method comprising exposing to the cell and effective amount of a compound of formula I.
The present invention also provides methods for the treatment or prevention of diseases and disorders associated with reduced or otherwise aberrant apoptosis.
Accordingly, one aspect of the invention provides a method for preventing or treating a disease or disorder in a subject, the method comprising administering to the subject an effective amount of a compound of formula I, wherein the compound induces or promotes apoptosis in at least one cell of the subject. Optionally, the compound is administered in the form of a pharmaceutical composition, which may comprise one or more pharmaceutically acceptable diluents, adjuvants and/or excipients.
It will also be readily appreciated by those skilled in the art that the present invention contemplates the administration of more than one compound of formula I, and/or the administration of at least one compound of formula I in conjunction with at least one additional therapeutic compound or agent.
Compounds useful in the present invention are of the general formula (I):
Rl io ~ = m Rio Rs Y
wherein Ri is hydrogen, hydroxy, alkyl, alkoxy, halo or OC(O)R7, R2 and R3 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, halo or OC(O)R7, R4, Rs and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, amino, C14-alkylamino or di(Ci-4-alkyl)amino, OC(O)R7 or OR8, R7 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl or amino, and R8 is aryl or arylalkyl, Rs and Rio are independently hydrogen, hydroxy, alkyl, alkoxy or halo, and the drawing "=" represents a single bond or a double bond, or a pharmaceutically acceptable salt or derivative thereof.
Accordingly, one aspect of the invention provides a method for preventing or treating a disease or disorder in a subject, the method comprising administering to the subject an effective amount of a compound of formula I, wherein the compound induces or promotes apoptosis in at least one cell of the subject. Optionally, the compound is administered in the form of a pharmaceutical composition, which may comprise one or more pharmaceutically acceptable diluents, adjuvants and/or excipients.
It will also be readily appreciated by those skilled in the art that the present invention contemplates the administration of more than one compound of formula I, and/or the administration of at least one compound of formula I in conjunction with at least one additional therapeutic compound or agent.
Compounds useful in the present invention are of the general formula (I):
Rl io ~ = m Rio Rs Y
wherein Ri is hydrogen, hydroxy, alkyl, alkoxy, halo or OC(O)R7, R2 and R3 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, halo or OC(O)R7, R4, Rs and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, amino, C14-alkylamino or di(Ci-4-alkyl)amino, OC(O)R7 or OR8, R7 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl or amino, and R8 is aryl or arylalkyl, Rs and Rio are independently hydrogen, hydroxy, alkyl, alkoxy or halo, and the drawing "=" represents a single bond or a double bond, or a pharmaceutically acceptable salt or derivative thereof.
Typically in compounds of formula (I) the substitution pattern of R2 and Rs is as shown below:
R3 /or T11III5R2 In compounds of formula (I) the substitution pattern of R4, R5 and R6 may be as shown below:
R5 R5 Rs R4 Rq R5 R6 \ Rs or I /
In compounds of formula (I) the drawing "-^" may represent a single bond.
In an embodiment, in compounds of formula (I):
Ri is hydroxy, C1.a-alkoxy or OC(O)R7, R2 and Rs are independently hydrogen, hydroxy, C1a-aikoxy, halo or OC(O)R7, R4, R5 and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, OC(O)R7, and R7 is Ci.a-alkyl, phenyl or benzyl, Rs is hydrogen, hydroxy, aikyi or halo, or a pharmaceutically acceptable salt or derivative thereof.
In an embodiment, in compounds of formula (I):
Ri is hydroxy, methoxy, ethoxy or acetyloxy, R2 and R3 are independently hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy, bromo, chloro, fluoro or acetyloxy, R4 is hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy or acetyloxy, and R5 and R6 are independently hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy, acetyl, or acetyloxy, Rs is hydrogen, hydroxy, methyl, methoxy, bromo, chloro, fluoro or acetyloxy, Rio is hydrogen, or a pharmaceutically acceptable salt or derivative thereof.
Compounds of formula (I) may have the following substituents where:
Ri is hydroxy, methoxy or acetyloxy, R2 and R3 are independently hydrogen, hydroxy, methoxy, bromo or acetyloxy, R4 and R6 are independently hydrogen, hydroxy, methoxy or acetyloxy, R5 and Rio are hydrogen, and Rs is hydrogen, methyl or bromo, or a pharmaceutically acceptable salt or derivative thereof.
In an embodiment, Rs is methyl.
According to embodiments of the invention compounds of formula (I) include:
3-(4-hydroxyphenyl)-4-(4-methoxyphenyi)-8-methylchroman-7-ol (Compound 1);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylchroman (Compound 2);
3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyi)-8-methylchroman-7-oI (Compound 3);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 4);
3-(4-hyd roxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylch roman (Compound 5);
3-(3-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 6);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylchroman (Compound 7);
3-(3-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 8);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 9);
R3 /or T11III5R2 In compounds of formula (I) the substitution pattern of R4, R5 and R6 may be as shown below:
R5 R5 Rs R4 Rq R5 R6 \ Rs or I /
In compounds of formula (I) the drawing "-^" may represent a single bond.
In an embodiment, in compounds of formula (I):
Ri is hydroxy, C1.a-alkoxy or OC(O)R7, R2 and Rs are independently hydrogen, hydroxy, C1a-aikoxy, halo or OC(O)R7, R4, R5 and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, OC(O)R7, and R7 is Ci.a-alkyl, phenyl or benzyl, Rs is hydrogen, hydroxy, aikyi or halo, or a pharmaceutically acceptable salt or derivative thereof.
In an embodiment, in compounds of formula (I):
Ri is hydroxy, methoxy, ethoxy or acetyloxy, R2 and R3 are independently hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy, bromo, chloro, fluoro or acetyloxy, R4 is hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy or acetyloxy, and R5 and R6 are independently hydrogen, hydroxy, methoxy, ethoxy, propoxy, isopropoxy, acetyl, or acetyloxy, Rs is hydrogen, hydroxy, methyl, methoxy, bromo, chloro, fluoro or acetyloxy, Rio is hydrogen, or a pharmaceutically acceptable salt or derivative thereof.
Compounds of formula (I) may have the following substituents where:
Ri is hydroxy, methoxy or acetyloxy, R2 and R3 are independently hydrogen, hydroxy, methoxy, bromo or acetyloxy, R4 and R6 are independently hydrogen, hydroxy, methoxy or acetyloxy, R5 and Rio are hydrogen, and Rs is hydrogen, methyl or bromo, or a pharmaceutically acceptable salt or derivative thereof.
In an embodiment, Rs is methyl.
According to embodiments of the invention compounds of formula (I) include:
3-(4-hydroxyphenyl)-4-(4-methoxyphenyi)-8-methylchroman-7-ol (Compound 1);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylchroman (Compound 2);
3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyi)-8-methylchroman-7-oI (Compound 3);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 4);
3-(4-hyd roxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylch roman (Compound 5);
3-(3-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 6);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-7-methoxy-8-methylchroman (Compound 7);
3-(3-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 8);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (Compound 9);
or a pharmaceutically acceptable salt thereof.
In another embodiment, Rs is hydrogen.
According to additional embodiments compounds of formula (I) include:
3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol (Compound 10);
3-(4-hydroxyphenyl)-4-phenylchroman-7-ol (Compound 11);
3-(4-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-oI (Compound 12);
3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol (Compound 13);
3-(4-hydroxyphenyl)-4-(4-methylphenyl)chroman-7-ol (Compound 14);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-7-methoxychroman (Compound 15);
3-(4-hydroxyphenyl)-4-(2,6-dimethoxy-4-hydroxyphenyl)chroman-7-oI (Compound 16);
3-(4-hydroxyphenyl)-4-(2-hydroxyphenyl)chroman-7-oI (Compound 17);
3-(4-hydroxyphenyl)-4-(3-acyl-2-hydroxy-4-methoxyphenyl)chroman-7-oi (Compound 18);
3-(3-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-o1(Compound 19);
3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)chroman-7-oI (Compound 20);
3-(4-bromophenyl)-4-(4-methoxyphenyl)chroman-7-oI (Compound 21);
3-(4-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-oI (Compound 22);
3-(4-hydroxyphenyl)-4-(3-aminophenyl)chroman-7-oI (Compound 23);
3-(4-hydroxyphenyl)-4-(4-phenoxyphenyl)chroman-7-oI (Compound 24);
or a pharmaceutically acceptable salt thereof.
The compounds of formula (I) according to the invention include two chiral centres. The present invention includes all the enantiomers and diastereoisomers as well as mixtures thereof in any proportions. The invention also extends to isolated enantiomers or pairs of enantiomers. Methods of separating enantiomers and diastereolsomers are well known to person skilled in the art.
It will be clear to persons skilled in the art that in the compounds of formula (I) the aryl substituents on the heterocyclic ring can be cis or trans relative to each other.
Compounds to which particular embodiments of the present invention relate are:
In another embodiment, Rs is hydrogen.
According to additional embodiments compounds of formula (I) include:
3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol (Compound 10);
3-(4-hydroxyphenyl)-4-phenylchroman-7-ol (Compound 11);
3-(4-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-oI (Compound 12);
3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol (Compound 13);
3-(4-hydroxyphenyl)-4-(4-methylphenyl)chroman-7-ol (Compound 14);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-7-methoxychroman (Compound 15);
3-(4-hydroxyphenyl)-4-(2,6-dimethoxy-4-hydroxyphenyl)chroman-7-oI (Compound 16);
3-(4-hydroxyphenyl)-4-(2-hydroxyphenyl)chroman-7-oI (Compound 17);
3-(4-hydroxyphenyl)-4-(3-acyl-2-hydroxy-4-methoxyphenyl)chroman-7-oi (Compound 18);
3-(3-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-o1(Compound 19);
3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)chroman-7-oI (Compound 20);
3-(4-bromophenyl)-4-(4-methoxyphenyl)chroman-7-oI (Compound 21);
3-(4-hydroxyphenyl)-4-(3-methoxyphenyl)chroman-7-oI (Compound 22);
3-(4-hydroxyphenyl)-4-(3-aminophenyl)chroman-7-oI (Compound 23);
3-(4-hydroxyphenyl)-4-(4-phenoxyphenyl)chroman-7-oI (Compound 24);
or a pharmaceutically acceptable salt thereof.
The compounds of formula (I) according to the invention include two chiral centres. The present invention includes all the enantiomers and diastereoisomers as well as mixtures thereof in any proportions. The invention also extends to isolated enantiomers or pairs of enantiomers. Methods of separating enantiomers and diastereolsomers are well known to person skilled in the art.
It will be clear to persons skilled in the art that in the compounds of formula (I) the aryl substituents on the heterocyclic ring can be cis or trans relative to each other.
Compounds to which particular embodiments of the present invention relate are:
Compound 1(including the cis-isomer thereof) Me HO O
OH
OMe or a pharmaceutically acceptable salt thereof; and Compound 10 HO O
OH
OMe or a pharmaceutically acceptable salt thereof.
The term "alkyl" is taken to include straight chain and branched chain saturated alkyl groups of 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertiary butyl, pentyl and the like. The alkyl group more preferably contains preferably from 1 to 4 carbon atoms, especially methyl, ethyl, propyl or isopropyl.
Cycloalkyl includes C3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The alkyl group or cycloalkyl group may optionally be substituted by one or more of fluorine, chlorine, bromine, iodine, carboxyl, Cl-C4-alkoxycarbonyl, Cl-Ca-alkylamino-carbonyl, di-(Ci-C4:-alkyl)-amino-carbonyl, hydroxyl, Cl-C4-alkoxy, formyloxy, Cl-Ca-alkyl-carbonyloxy, Cl-C4-alkylthio, C3-C6-cycloalkyl or phenyl. The alkyl group may not bear any substituents.
The term "aryl" is taken to include phenyl, benzyl, biphenyl and naphthyl and may be optionally substituted by one or more Cl-C4-alkyl, hydroxy, CI-C4-alkoxy, carbonyl, Cl-C4-alkoxycarbonyl, Cr Ca-alkylcarbonyloxy, nitro or halo.
The term "halo" is taken to include fluoro, chloro, bromo and iodo, preferably fluoro and chloro, more preferably fluoro. Reference to for example "haloalkyl" will include monohalogenated, dihalogenated and up to perhalogenated alkyl groups. Preferred haloalkyl groups are trifluoromethyl and pentafluoroethyl.
The compounds of the invention include all salts, such as acid addition salts, anionic salts and zwitterionic salts, and in particular include pharmaceutically acceptable salts as would be known to those skilled in the art. Pharmaceutically acceptable salts include those formed from: acetic, ascorbic, aspartic, benzoic, benzenesulphonic, citric, cinnamic, ethanesulphonic, fumaric, glutamic, glutaric, gluconic, hydrochloric, hydrobromic, lactic, maleic, malic, methanesulphonic, naphthoic, hydroxynaphthoic, naphthalenesulphonic, naphthalenedisulphonic, naphthaleneacrylic, oleic, oxalic, oxaloacetic, phosphoric, pyruvic, p-toluenesulphonic, tartaric, trifluoroacetic, triphenylacetic, tricarballylic, salicylic, sulphuric, sulphamic, sulphanilic and succinic acid.
Pharmaceutically acceptable derivatives include solvates, pharmaceutically active esters, prodrugs or the like. This also includes derivatives with physiologically cleavable leaving groups that can be cleaved in vivo to provide the compounds of the invention or their active moiety. The leaving groups may include acyl, phosphate, sulfate, sulfonate, and preferably are mono-, di-and per-acyl oxy-substituted compounds, where one or more of the pendant hydroxy groups are protected by an acyl group, preferably an acetyl group. Typically acyloxy substituted compounds of the invention are readily cleavable to the corresponding hydroxy substituted compounds.
Compounds of formula I to which the present invention relates are believed to have favourable toxicity profiles with normal cells and good bioavailability. These compounds are described in Intemational Patent Applications PCT/AU2005/001435 (published as WO
2006/032085) and PCT/AU2005/001436 (published as WO 2006/032086), the disclosures of which are incorporated herein by reference.
mTOR (mammalian Target of Rapamycin) is a serine/threonine protein kinase involved in the regulation of cell growth and proliferation, cell survival, cell motility and protein synthesis (see Hay and Sonenberg, 2004). An important function of mTOR is the control of translation via regulation of S6k and 4EBP1. Ac6vation of the pathway results in enhanced translation, enhanced cell mass, and cell cycle progression. mTOR is also an essential part of tumor progression capable of integrating proliferative, antiapoptotic, and angiogenic signaffing. There is increasing interest in the therapeutic application of mTOR inhibitors, exemplified by sirolimus and more recently the sirolimus analogs temsirolimus and everolimus, for treating a variety of diseases and conditions, including restenosis, transplant rejection and rheumatoid arthritis.
Embodiments of the present invention find particular application in the therapeutic or prophylactic treatment of diseases and conditions which are associated with aberrant or otherwise unwanted cell growth and/or proliferation and diseases and conditions in which the inhibition of mTOR activity is beneficial. As used herein the term "associated with" as used with reference to diseases and conditions associated with aberrant or otherwise unwanted cell growth and/or proliferation, means that a disease or condition may be caused by, may cause, or may otherwise be associated with abnormal cellular proliferation. The abnormal cellular proliferation may be in any cell type, including for example a myocardial or immune cell (typically a proliferating or abnormally proliferating T cell).
Preferably the cell is not a cancer cell.
Thus, suitable diseases and conditions to which embodiments of the invention find applicability include, but are not limited to, stenosis, restenosis, transplant rejection and rheumatoid arthritis and diseases and conditions associated with abnormal immune cell proliferation or activation. By way of example, the isoflavonoid compounds may be administered in the period immediately prior to and following vascular intervention such as coronary or vascular angioplasty as a means to reduce or eliminate the abnormal proliferative response that currently leads to clinically significant restenosis.
The transplant rejection may be of any tissue or organ. Those skilled in the art will appreciate that a wide range of diseases and conditions are associated with aberrant or otherwise unwanted cell growth and/or proliferation and the present invention finds applicability in the treatment of any such disease or condition.
Embodiments of the present invention find application in the inhibition of immune cell proliferation by the induction of apoptosis and thus in the therapeutic and prophylactic treatment of diseases or conditions associated with abnormal immune cell, particularly T cell, proliferation or stimulation.
Typically, in the context of the present invention, abnormal T cell proliferation means abnormally rapid proliferation. Diseases and conditions include, by way of non-limiting example, T cell leukemias, autoimmune diseases, and transplant or graft rejections such as graft versus host disease. Autoimmune diseases include, but are not limited to, cirrhosis, psoriasis, lupus, rheumatoid arthritis, Addison's disease, infectious mononucleosis, Sezary's syndrome and Epstein-Barr virus infection. Those skilled in the art will appreciate that a wide range of diseases and conditions are associated with abnormal T cell proliferation and the present invention finds applicability in the treatment of any such disease or condition.
Compounds as described herein may be administered alone or in conjunction with other active agents for treating diseases and conditions associated with aberrant or otherwise unwanted cell growth and/or proliferation and diseases and conditions in which the inhibition of mTOR activity is beneficial. By way of example, for the treatment of restenosis, compounds of the invention may be administered together with other mTOR inhibitors such as sirolimus, temsirolimus or everolimus.
Where such combination therapy is to be administered the active agents may be administered sequentially or simultaneously.
Also provided herein are methods for augmenting existing treatment regimes for subjects suffering from diseases or conditions that are associated with aberrant or otherwise unwanted cell growth and/or proliferation, the methods comprising administering to subjects in need thereof an effective amount of a compound of formula I as described herein or a pharmaceutically acceptable salt or prodrug thereof. Thus, for example, it is contemplated that compounds as described herein may be used in conjunction with existing therapeutic treatments for a range of diseases and conditions where a reduction in proliferating T cell activity and/or proliferation would be of benefit. That is, the administration of an immunomodulating effective amount of a compound described herein may improve the ability of a patient to respond to an existing treatment for the disease or condition suffered by the patient.
By "immunomodulating effective amount" is meant an amount or dose of the compound that is sufficient to modulate the immune system or immune response as desired. This immunomodulating amount may be a subtherapeutic dose of the compound, where a therapeutic dose is a dose that is sufficient to have a non-immunomodulatory, therapeutic effect against a particular disease or condition. That is, a smaller amount or dose of the compound may be administered to achieve an immunomodulatory effect than the amount or dose required to be administered to achieve a non-immunomodulatory therapeutic effect.
According to the methods of present invention isoflavonoid compounds and compositions comprising such isoflavonoids may be administered by any suitable route, either systemically, regionally or locally. The particular route of administration to be used in any given circumstance will depend on a number of factors, including the nature of the condition to be treated, the severity and extent of the condition, the required dosage of the particular compound to be delivered and the potential side-effects of the compound. For example, in circumstances where it is required that appropriate concentrations of the desired compound are delivered directly to the site in the body to be treated, administration may be regional rather than systemic. Regional administration provides the capability of delivering very high local concentrations of the desired compound to the required site and thus is suitable for achieving the desired therapeutic or preventative effect whilst avoiding exposure of other organs of the body to the compound and thereby potentially reducing side effects.
By way of example, administration according to embodiments of the invention may be achieved by any standard routes, including intracavitary, intravesical, intramuscular, intraarterial, intravenous, intraocular, subcutaneous, topical or oral.
According to particular embodiments of the present invention isoflavonoid compounds and compositions comprising such isoflavonoids may be incorporated into implantable medical devices for administration. Stents and catheters in particular are adapted to be implanted into a patient's body lumen, such as a blood vessel e.g. coronary artery, bile ducts, oesophagus, colon, trachea or large bronchi, ureters and urethra. Stents are particularly useful in the treatment of atherosclerotic stenosis and aneurysms.
Stents are typically implanted within a vessel or lumen in a contracted state, and can be expanded when in place in the vessel in order to maintain the patency of the vessel to allow fluid flow through the vessel. Stents have a support structure such as a metallic structure to provide the strength required and are often provided with an exterior surface coating to provide a biocompatible and/or hemocompatible surface. The coating is typically a polymeric material and may be loaded with therapeutically active agents for release at a specific intravascular site for action on the surrounding vessel or downstream thereof.
Drug-eluting stents have shown great promise in treating coronary artery disease, specifically in terms of reopening and restoring blood flow in arteries stenosed by atherosclerosis. Restenosis rates after using drug-eluting stents during percutaneous intervention are significantly lower compared to bare metal stenting and balloon angioplasty.
As will be appreciated by those having ordinary skill in the art, a drug-eluting stent used in accordance with the present invention can be virtually of any type. The drug-eluting stent may be formed at least in part of a medical grade metallic material such as stainless steel, platinum, titanium, tantalum, nickel-titanium, cobalt-chromium, and alloys thereof. The stents may also be made of bioabsorbable material. Typically these stents are fully resorbable structures having metal-like scaffolding, generally use standard balloon deployment, and can be loaded with drug. Examples of the materials with which bioabsorbable stents can be made is polylactic acid (PLA), a biodegradable, thermoplastic, aliphatic polyester, or polylactic-co-glycolic acid (PLGA), a biodegradable biocompatible copolymer or magnesium.
The active agent can be attached to the implantable medical device surface by any means that provides a drug-releasing platform. Binding can be achieved covalently, ionically, or through other molecular interactions including hydrogen bonding and van der Waals forces.
Coating methods include, but are not limited to precipitation, coacervation, and crystallization. More typically, the active agent is complexed with a suitable biocompatible polymer. The polymer-drug complex is then used to either form a controlled-release medical device, integrated into a preformed medical device or used to coat a medical device as would be well known to a person skilled in the art. The coatings can be applied as a liquid polymerlsolvent matrix. The liquid coating can be applied by pad printing, inkjet printing, rolling, painting, spraying, micro-spraying, dipping, wiping, electrostatic deposition, vapour deposition, epitaxial growth, combinations thereof and other methods of achieving controlled drug release with the active agents are contemplated as being part of the present invention.
Examples of suitable polymers for use in coating the implantable medical devices include poly(ethylene-co-vinyl alcohol) (EVAL), poly(N-vinylpyrrolidone) (PVP), ethyl cellulose, cellulose acetate, carboxymethyl cellulose, cellulosics, chitin, chitosan, poly(vinyl alcohol), heparin, dextran, dextrin, dextran sulfate, collagen, gelatin, hyaluronic acid, chondroitan sulfate, glycosaminoglycans, poly[(2-hydroxyethyl)methylmethacrylate], polyurethanes, poly(ether urethanes), poly(ester urethanes), poly(carbonate urethanes), thermoplastic polyesters, solvent soluble nylons, poly(acrylamide), poly(acrylic acid), copolymers of acrylic acid and acrylates, poly(methacrylic acid), copolymers of methacrylic acid and methacrylates, and blends thereof.
Persons skilled in the art will appreciate that different polymers are better suited to different solvents in the formation of the medical device coatings. Examples of suitable solvents include acetone, ethyl acetate, chloroform, dichloromethane, DMAC, DMSO, DMF, THF, formamide, N-methyl-2-pyrrolidone (NMP), sulfolane, benzyl alcohol, cyclohexanol, phenol, formic acid, m-cresol, p-cresol, trifluoroacetic acid, glycerol, ethylene glycol, propylene glycol, ethanol, propanois and mixtures thereof. The active agent must also be suitably soluble or dispersible in the polymer/solvent mixture and retain its activity during the coating process. The polymer may be adhered to the stent using conventional metal-polymer adhesion techniques, such as by dipping, spraying, wiping, and brushing, which are known in the art. These processes may be followed by web clearing operations that can include blowing air or spinning and drying operations including evaporation, heating and subjecting the coating to reduced pressure to remove the solvent and set the drug containing polymer. The polymer coating can have a thickness in the range of about 1 micron to about 10 microns or more and more that one coating may be desired including primer coatings and protective layer coatings.
The active agent loading is typically between about 0.1 and about 10 mass % of the total mass of the formulation used to make the drug-polymer layer. The drug can include additional substances capable of exerting a therapeutic or prophylactic effect for a patient or for use in increasing drug delivery, as a preservative, stabiliser or the like.
Therapeutic drugs suitable for co-application on stents include, but are not limited to, antiproliferatives including paclitaxel and rapamyacin, antithrombins, immunosuppressants including sirolimus, antilipid agents, anti-inflammatory agents, antineoplastics, antiplatelets, angiogenic agents, anti-angiogenic agents, vitamins, antimitotics, metalloproteinase inhibitors, NO donors, estradiols, anti-sclerosing agents, and vasoactive agents, endothelial growth factors, estrogen, beta blockers, AZ blockers, hormones, statins, insulin growth factors, antioxidants, membrane stabilizing agents, calcium antagonists, retenoid, bivalirudin, phenoxodiol, etoposide, ticlopidine, dipyridamole and trapidil alone or in combinations with any therapeutic agent mentioned herein. Therapeutic agents also include peptides, lipoproteins, polypeptides, polynucleotides encoding polypeptides, lipids, protein-drugs, protein conjugate drugs, enzymes, oligonucleotides and their derivatives, ribozymes, other genetic material, cells, antisense, oligonucleotides, monoclonal antibodies, platelets, prions, viruses, bacteria, and eukaryotic cells such as endothelial cells, stem cells, ACE
inhibitors, monocytelmacrophages or vascular smooth muscle cells to name but a few examples.
The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. In addition, therapeutic agents may be pre-formulated as microcapsules, microspheres, microbubbles, liposomes, niosomes, emulsions, dispersions or the like before they are incorporated into the therapeutic layer. Therapeutic agents may also be radioactive isotopes or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered. Therapeutic agents may perform multiple functions including modulating angiogenesis, restenosis, cell proliferation, thrombosis, platelet aggregation, clotting and vasodilation. Anti-inflammatories include non-steroidal anti-inflammatories (NSAID), such as aryl acetic acid derivatives, e.g., Diclofenac; aryl propionic acid derivatives, e.g., Naproxen; and salicylic acid derivatives, e.g., aspirin and Diflunisal. Anti-inflammatories also include glucocoriticoids (steroids) such as dexamethasone, prednisolone and triamcinolone. Anti-inflammatories may be used in combination with antiproliferatives to mitigate the reaction of the tissue to the antiproliferative.
Drug-eluting stents and catheters as described herein may be utilised in any part of the vasculature including neurological, carotid, coronary, renal, aortic, iliac, femoral or other peripheral vasculature.
The stents can deliver the active agents to the site of implantation or downstream of the site.
The drug-eluting stents can have multiple layers created independently and as such individual chemical compositions and pharmacokinetic properties can be imparted to each layer. Each of the layers may include one or more agents in the same or different proportions from layer to layer.
Changes in the agent concentration between layers can be used to achieve a desired delivery profile. For example, a decreasing release of drug for about 24 hours can be achieved. In another example, an initial burst followed by a constant release for about one week can be achieved. Other examples can deliver an agent over a sustained period of time, such as several days to several months. Substantially constant release rates over time period from a few hours to months can be achieved. The layers may be solid, porous, or filled with other drugs or excipients and the like.
In employing methods of the invention, isoflavonoid compounds may be formulated in pharmaceutical compositions. Suitable compositions may be prepared according to methods which are known to those of ordinary skill in the art and may include a pharmaceutically acceptable diluent, adjuvant and/or excipient. The diluents, adjuvants and excipients must be "acceptable" in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof. The diluent, adjuvant or excipient may be a solid or a liquid, or both, and may be formulated with the compound as a unit-dose, for example, a tablet, which may contain from 0.5% to 59% by weight of the active compound, or up to 100% by weight of the active compound.
One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.
Examples of pharmaceutically acceptable diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butylene glycol or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinyipyrridone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 1% to 99.9%
by weight of the compositions.
Formulations suitable for oral administration may be presented in discrete units, such as capsules, sachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).
In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture such as to form a unit dosage. For example, a tablet may be prepared by compressing or moulding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound of the free-flowing, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s).
Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
OH
OMe or a pharmaceutically acceptable salt thereof; and Compound 10 HO O
OH
OMe or a pharmaceutically acceptable salt thereof.
The term "alkyl" is taken to include straight chain and branched chain saturated alkyl groups of 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertiary butyl, pentyl and the like. The alkyl group more preferably contains preferably from 1 to 4 carbon atoms, especially methyl, ethyl, propyl or isopropyl.
Cycloalkyl includes C3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The alkyl group or cycloalkyl group may optionally be substituted by one or more of fluorine, chlorine, bromine, iodine, carboxyl, Cl-C4-alkoxycarbonyl, Cl-Ca-alkylamino-carbonyl, di-(Ci-C4:-alkyl)-amino-carbonyl, hydroxyl, Cl-C4-alkoxy, formyloxy, Cl-Ca-alkyl-carbonyloxy, Cl-C4-alkylthio, C3-C6-cycloalkyl or phenyl. The alkyl group may not bear any substituents.
The term "aryl" is taken to include phenyl, benzyl, biphenyl and naphthyl and may be optionally substituted by one or more Cl-C4-alkyl, hydroxy, CI-C4-alkoxy, carbonyl, Cl-C4-alkoxycarbonyl, Cr Ca-alkylcarbonyloxy, nitro or halo.
The term "halo" is taken to include fluoro, chloro, bromo and iodo, preferably fluoro and chloro, more preferably fluoro. Reference to for example "haloalkyl" will include monohalogenated, dihalogenated and up to perhalogenated alkyl groups. Preferred haloalkyl groups are trifluoromethyl and pentafluoroethyl.
The compounds of the invention include all salts, such as acid addition salts, anionic salts and zwitterionic salts, and in particular include pharmaceutically acceptable salts as would be known to those skilled in the art. Pharmaceutically acceptable salts include those formed from: acetic, ascorbic, aspartic, benzoic, benzenesulphonic, citric, cinnamic, ethanesulphonic, fumaric, glutamic, glutaric, gluconic, hydrochloric, hydrobromic, lactic, maleic, malic, methanesulphonic, naphthoic, hydroxynaphthoic, naphthalenesulphonic, naphthalenedisulphonic, naphthaleneacrylic, oleic, oxalic, oxaloacetic, phosphoric, pyruvic, p-toluenesulphonic, tartaric, trifluoroacetic, triphenylacetic, tricarballylic, salicylic, sulphuric, sulphamic, sulphanilic and succinic acid.
Pharmaceutically acceptable derivatives include solvates, pharmaceutically active esters, prodrugs or the like. This also includes derivatives with physiologically cleavable leaving groups that can be cleaved in vivo to provide the compounds of the invention or their active moiety. The leaving groups may include acyl, phosphate, sulfate, sulfonate, and preferably are mono-, di-and per-acyl oxy-substituted compounds, where one or more of the pendant hydroxy groups are protected by an acyl group, preferably an acetyl group. Typically acyloxy substituted compounds of the invention are readily cleavable to the corresponding hydroxy substituted compounds.
Compounds of formula I to which the present invention relates are believed to have favourable toxicity profiles with normal cells and good bioavailability. These compounds are described in Intemational Patent Applications PCT/AU2005/001435 (published as WO
2006/032085) and PCT/AU2005/001436 (published as WO 2006/032086), the disclosures of which are incorporated herein by reference.
mTOR (mammalian Target of Rapamycin) is a serine/threonine protein kinase involved in the regulation of cell growth and proliferation, cell survival, cell motility and protein synthesis (see Hay and Sonenberg, 2004). An important function of mTOR is the control of translation via regulation of S6k and 4EBP1. Ac6vation of the pathway results in enhanced translation, enhanced cell mass, and cell cycle progression. mTOR is also an essential part of tumor progression capable of integrating proliferative, antiapoptotic, and angiogenic signaffing. There is increasing interest in the therapeutic application of mTOR inhibitors, exemplified by sirolimus and more recently the sirolimus analogs temsirolimus and everolimus, for treating a variety of diseases and conditions, including restenosis, transplant rejection and rheumatoid arthritis.
Embodiments of the present invention find particular application in the therapeutic or prophylactic treatment of diseases and conditions which are associated with aberrant or otherwise unwanted cell growth and/or proliferation and diseases and conditions in which the inhibition of mTOR activity is beneficial. As used herein the term "associated with" as used with reference to diseases and conditions associated with aberrant or otherwise unwanted cell growth and/or proliferation, means that a disease or condition may be caused by, may cause, or may otherwise be associated with abnormal cellular proliferation. The abnormal cellular proliferation may be in any cell type, including for example a myocardial or immune cell (typically a proliferating or abnormally proliferating T cell).
Preferably the cell is not a cancer cell.
Thus, suitable diseases and conditions to which embodiments of the invention find applicability include, but are not limited to, stenosis, restenosis, transplant rejection and rheumatoid arthritis and diseases and conditions associated with abnormal immune cell proliferation or activation. By way of example, the isoflavonoid compounds may be administered in the period immediately prior to and following vascular intervention such as coronary or vascular angioplasty as a means to reduce or eliminate the abnormal proliferative response that currently leads to clinically significant restenosis.
The transplant rejection may be of any tissue or organ. Those skilled in the art will appreciate that a wide range of diseases and conditions are associated with aberrant or otherwise unwanted cell growth and/or proliferation and the present invention finds applicability in the treatment of any such disease or condition.
Embodiments of the present invention find application in the inhibition of immune cell proliferation by the induction of apoptosis and thus in the therapeutic and prophylactic treatment of diseases or conditions associated with abnormal immune cell, particularly T cell, proliferation or stimulation.
Typically, in the context of the present invention, abnormal T cell proliferation means abnormally rapid proliferation. Diseases and conditions include, by way of non-limiting example, T cell leukemias, autoimmune diseases, and transplant or graft rejections such as graft versus host disease. Autoimmune diseases include, but are not limited to, cirrhosis, psoriasis, lupus, rheumatoid arthritis, Addison's disease, infectious mononucleosis, Sezary's syndrome and Epstein-Barr virus infection. Those skilled in the art will appreciate that a wide range of diseases and conditions are associated with abnormal T cell proliferation and the present invention finds applicability in the treatment of any such disease or condition.
Compounds as described herein may be administered alone or in conjunction with other active agents for treating diseases and conditions associated with aberrant or otherwise unwanted cell growth and/or proliferation and diseases and conditions in which the inhibition of mTOR activity is beneficial. By way of example, for the treatment of restenosis, compounds of the invention may be administered together with other mTOR inhibitors such as sirolimus, temsirolimus or everolimus.
Where such combination therapy is to be administered the active agents may be administered sequentially or simultaneously.
Also provided herein are methods for augmenting existing treatment regimes for subjects suffering from diseases or conditions that are associated with aberrant or otherwise unwanted cell growth and/or proliferation, the methods comprising administering to subjects in need thereof an effective amount of a compound of formula I as described herein or a pharmaceutically acceptable salt or prodrug thereof. Thus, for example, it is contemplated that compounds as described herein may be used in conjunction with existing therapeutic treatments for a range of diseases and conditions where a reduction in proliferating T cell activity and/or proliferation would be of benefit. That is, the administration of an immunomodulating effective amount of a compound described herein may improve the ability of a patient to respond to an existing treatment for the disease or condition suffered by the patient.
By "immunomodulating effective amount" is meant an amount or dose of the compound that is sufficient to modulate the immune system or immune response as desired. This immunomodulating amount may be a subtherapeutic dose of the compound, where a therapeutic dose is a dose that is sufficient to have a non-immunomodulatory, therapeutic effect against a particular disease or condition. That is, a smaller amount or dose of the compound may be administered to achieve an immunomodulatory effect than the amount or dose required to be administered to achieve a non-immunomodulatory therapeutic effect.
According to the methods of present invention isoflavonoid compounds and compositions comprising such isoflavonoids may be administered by any suitable route, either systemically, regionally or locally. The particular route of administration to be used in any given circumstance will depend on a number of factors, including the nature of the condition to be treated, the severity and extent of the condition, the required dosage of the particular compound to be delivered and the potential side-effects of the compound. For example, in circumstances where it is required that appropriate concentrations of the desired compound are delivered directly to the site in the body to be treated, administration may be regional rather than systemic. Regional administration provides the capability of delivering very high local concentrations of the desired compound to the required site and thus is suitable for achieving the desired therapeutic or preventative effect whilst avoiding exposure of other organs of the body to the compound and thereby potentially reducing side effects.
By way of example, administration according to embodiments of the invention may be achieved by any standard routes, including intracavitary, intravesical, intramuscular, intraarterial, intravenous, intraocular, subcutaneous, topical or oral.
According to particular embodiments of the present invention isoflavonoid compounds and compositions comprising such isoflavonoids may be incorporated into implantable medical devices for administration. Stents and catheters in particular are adapted to be implanted into a patient's body lumen, such as a blood vessel e.g. coronary artery, bile ducts, oesophagus, colon, trachea or large bronchi, ureters and urethra. Stents are particularly useful in the treatment of atherosclerotic stenosis and aneurysms.
Stents are typically implanted within a vessel or lumen in a contracted state, and can be expanded when in place in the vessel in order to maintain the patency of the vessel to allow fluid flow through the vessel. Stents have a support structure such as a metallic structure to provide the strength required and are often provided with an exterior surface coating to provide a biocompatible and/or hemocompatible surface. The coating is typically a polymeric material and may be loaded with therapeutically active agents for release at a specific intravascular site for action on the surrounding vessel or downstream thereof.
Drug-eluting stents have shown great promise in treating coronary artery disease, specifically in terms of reopening and restoring blood flow in arteries stenosed by atherosclerosis. Restenosis rates after using drug-eluting stents during percutaneous intervention are significantly lower compared to bare metal stenting and balloon angioplasty.
As will be appreciated by those having ordinary skill in the art, a drug-eluting stent used in accordance with the present invention can be virtually of any type. The drug-eluting stent may be formed at least in part of a medical grade metallic material such as stainless steel, platinum, titanium, tantalum, nickel-titanium, cobalt-chromium, and alloys thereof. The stents may also be made of bioabsorbable material. Typically these stents are fully resorbable structures having metal-like scaffolding, generally use standard balloon deployment, and can be loaded with drug. Examples of the materials with which bioabsorbable stents can be made is polylactic acid (PLA), a biodegradable, thermoplastic, aliphatic polyester, or polylactic-co-glycolic acid (PLGA), a biodegradable biocompatible copolymer or magnesium.
The active agent can be attached to the implantable medical device surface by any means that provides a drug-releasing platform. Binding can be achieved covalently, ionically, or through other molecular interactions including hydrogen bonding and van der Waals forces.
Coating methods include, but are not limited to precipitation, coacervation, and crystallization. More typically, the active agent is complexed with a suitable biocompatible polymer. The polymer-drug complex is then used to either form a controlled-release medical device, integrated into a preformed medical device or used to coat a medical device as would be well known to a person skilled in the art. The coatings can be applied as a liquid polymerlsolvent matrix. The liquid coating can be applied by pad printing, inkjet printing, rolling, painting, spraying, micro-spraying, dipping, wiping, electrostatic deposition, vapour deposition, epitaxial growth, combinations thereof and other methods of achieving controlled drug release with the active agents are contemplated as being part of the present invention.
Examples of suitable polymers for use in coating the implantable medical devices include poly(ethylene-co-vinyl alcohol) (EVAL), poly(N-vinylpyrrolidone) (PVP), ethyl cellulose, cellulose acetate, carboxymethyl cellulose, cellulosics, chitin, chitosan, poly(vinyl alcohol), heparin, dextran, dextrin, dextran sulfate, collagen, gelatin, hyaluronic acid, chondroitan sulfate, glycosaminoglycans, poly[(2-hydroxyethyl)methylmethacrylate], polyurethanes, poly(ether urethanes), poly(ester urethanes), poly(carbonate urethanes), thermoplastic polyesters, solvent soluble nylons, poly(acrylamide), poly(acrylic acid), copolymers of acrylic acid and acrylates, poly(methacrylic acid), copolymers of methacrylic acid and methacrylates, and blends thereof.
Persons skilled in the art will appreciate that different polymers are better suited to different solvents in the formation of the medical device coatings. Examples of suitable solvents include acetone, ethyl acetate, chloroform, dichloromethane, DMAC, DMSO, DMF, THF, formamide, N-methyl-2-pyrrolidone (NMP), sulfolane, benzyl alcohol, cyclohexanol, phenol, formic acid, m-cresol, p-cresol, trifluoroacetic acid, glycerol, ethylene glycol, propylene glycol, ethanol, propanois and mixtures thereof. The active agent must also be suitably soluble or dispersible in the polymer/solvent mixture and retain its activity during the coating process. The polymer may be adhered to the stent using conventional metal-polymer adhesion techniques, such as by dipping, spraying, wiping, and brushing, which are known in the art. These processes may be followed by web clearing operations that can include blowing air or spinning and drying operations including evaporation, heating and subjecting the coating to reduced pressure to remove the solvent and set the drug containing polymer. The polymer coating can have a thickness in the range of about 1 micron to about 10 microns or more and more that one coating may be desired including primer coatings and protective layer coatings.
The active agent loading is typically between about 0.1 and about 10 mass % of the total mass of the formulation used to make the drug-polymer layer. The drug can include additional substances capable of exerting a therapeutic or prophylactic effect for a patient or for use in increasing drug delivery, as a preservative, stabiliser or the like.
Therapeutic drugs suitable for co-application on stents include, but are not limited to, antiproliferatives including paclitaxel and rapamyacin, antithrombins, immunosuppressants including sirolimus, antilipid agents, anti-inflammatory agents, antineoplastics, antiplatelets, angiogenic agents, anti-angiogenic agents, vitamins, antimitotics, metalloproteinase inhibitors, NO donors, estradiols, anti-sclerosing agents, and vasoactive agents, endothelial growth factors, estrogen, beta blockers, AZ blockers, hormones, statins, insulin growth factors, antioxidants, membrane stabilizing agents, calcium antagonists, retenoid, bivalirudin, phenoxodiol, etoposide, ticlopidine, dipyridamole and trapidil alone or in combinations with any therapeutic agent mentioned herein. Therapeutic agents also include peptides, lipoproteins, polypeptides, polynucleotides encoding polypeptides, lipids, protein-drugs, protein conjugate drugs, enzymes, oligonucleotides and their derivatives, ribozymes, other genetic material, cells, antisense, oligonucleotides, monoclonal antibodies, platelets, prions, viruses, bacteria, and eukaryotic cells such as endothelial cells, stem cells, ACE
inhibitors, monocytelmacrophages or vascular smooth muscle cells to name but a few examples.
The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. In addition, therapeutic agents may be pre-formulated as microcapsules, microspheres, microbubbles, liposomes, niosomes, emulsions, dispersions or the like before they are incorporated into the therapeutic layer. Therapeutic agents may also be radioactive isotopes or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered. Therapeutic agents may perform multiple functions including modulating angiogenesis, restenosis, cell proliferation, thrombosis, platelet aggregation, clotting and vasodilation. Anti-inflammatories include non-steroidal anti-inflammatories (NSAID), such as aryl acetic acid derivatives, e.g., Diclofenac; aryl propionic acid derivatives, e.g., Naproxen; and salicylic acid derivatives, e.g., aspirin and Diflunisal. Anti-inflammatories also include glucocoriticoids (steroids) such as dexamethasone, prednisolone and triamcinolone. Anti-inflammatories may be used in combination with antiproliferatives to mitigate the reaction of the tissue to the antiproliferative.
Drug-eluting stents and catheters as described herein may be utilised in any part of the vasculature including neurological, carotid, coronary, renal, aortic, iliac, femoral or other peripheral vasculature.
The stents can deliver the active agents to the site of implantation or downstream of the site.
The drug-eluting stents can have multiple layers created independently and as such individual chemical compositions and pharmacokinetic properties can be imparted to each layer. Each of the layers may include one or more agents in the same or different proportions from layer to layer.
Changes in the agent concentration between layers can be used to achieve a desired delivery profile. For example, a decreasing release of drug for about 24 hours can be achieved. In another example, an initial burst followed by a constant release for about one week can be achieved. Other examples can deliver an agent over a sustained period of time, such as several days to several months. Substantially constant release rates over time period from a few hours to months can be achieved. The layers may be solid, porous, or filled with other drugs or excipients and the like.
In employing methods of the invention, isoflavonoid compounds may be formulated in pharmaceutical compositions. Suitable compositions may be prepared according to methods which are known to those of ordinary skill in the art and may include a pharmaceutically acceptable diluent, adjuvant and/or excipient. The diluents, adjuvants and excipients must be "acceptable" in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof. The diluent, adjuvant or excipient may be a solid or a liquid, or both, and may be formulated with the compound as a unit-dose, for example, a tablet, which may contain from 0.5% to 59% by weight of the active compound, or up to 100% by weight of the active compound.
One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.
Examples of pharmaceutically acceptable diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butylene glycol or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinyipyrridone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 1% to 99.9%
by weight of the compositions.
Formulations suitable for oral administration may be presented in discrete units, such as capsules, sachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).
In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture such as to form a unit dosage. For example, a tablet may be prepared by compressing or moulding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound of the free-flowing, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s).
Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
Solid forms for oral administration may contain binders acceptable in human and veterinary pharmaceutical practice, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents. Suitable binders include gum acacia, gelatine, com starch, gum tragacanth, sodium alginate, carboxymethylcellulose or polyethylene glycol.
Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar. Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate.
Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
Liquid forms for oral administration may contain, in addition to the above agents, a liquid carrier.
Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
Formulations suitable for buccal (sublingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
Compositions of the present invention suitable for parenteral administration typically conveniently comprise sterile aqueous preparations of the active compounds, which preparations may be isotonic with the blood of the intended recipient. These preparations are typically administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and rendering the resulting solution sterile and isotonic with the blood.
Injectable formulations according to the invention generally contain from 0.1%
to 60% w/v of active compound(s) and are administered at a rate of 0.1 mllminute/kg or as appropriate.
Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar. Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate.
Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
Liquid forms for oral administration may contain, in addition to the above agents, a liquid carrier.
Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
Formulations suitable for buccal (sublingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
Compositions of the present invention suitable for parenteral administration typically conveniently comprise sterile aqueous preparations of the active compounds, which preparations may be isotonic with the blood of the intended recipient. These preparations are typically administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and rendering the resulting solution sterile and isotonic with the blood.
Injectable formulations according to the invention generally contain from 0.1%
to 60% w/v of active compound(s) and are administered at a rate of 0.1 mllminute/kg or as appropriate.
Formulations for infusion, for example, may be prepared employing saline as the carrier and a solubilising agent such as a cyclodextrin or derivative thereof. Suitable cyclodextrins include a-cyclodextrin, Q-cyclodextrin, y-cyclodextrin, dimethyl-R-cyclodextrin, 2-hydroxyethyl-R-cyclodextrin, 2-hydroxypropyl-cyclodextrin, 3-hydroxypropyl-p-cyclodextrin and tri-methyl-p-cyclodextrin. More preferably the cyclodextrin is hydroxypropyl-R-cyclodextrin. Suitable derivatives of cyclodextrins include Captisol a sulfobutyl ether derivative of cyclodextrin and analogues thereof as described in US 5,134,127.
Formulations suitable for rectal administration are typically presented as unit dose suppositories.
These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
Formulations or compositions suitable for topical administration to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combination of two or more thereof. The active compound is generally present at a concentration of from 0.1 % to 0.5%
w/w, for example, from 0.5% to 2% w/w. Examples of such compositions include cosmetic skin creams.
Formulations suitable for inhalation may be delivered as a spray composition in the form of a solution, suspension or emulsion. The inhalation spray composition may further comprise a pharmaceutically acceptable propellant such as carbon dioxide or nitrous oxide or a hydrogen containing fluorocarbon such as 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof.
Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound as an optionally buffered aqueous solution of, for example, 0.1 M to 0.2 M concentration with respect to the said active compound. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6), 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. For example, suitable formulations may comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 M to 0.2 M
active ingredient.
The active compounds may be provided in the form of food stuffs, such as being added to, admixed into, coated, combined or otherwise added to a food stuff. The term food stuff is used in its widest possible sense and includes liquid formulations such as drinks including dairy products and other foods, such as health bars, desserts, etc. Food formulations containing compounds of the invention can be readily prepared according to standard practices.
According to the present invention, compounds and compositions may be administered either therapeutically or preventively. In a therapeutic application, compounds and compositions are administered to a patient already suffering from a disease or disorder or experiencing symptoms, in an amount sufficient to cure or at least partially arrest the disease or disorder, symptoms andlor any associated complications. The compound or composition should provide a quantity of the active compound sufficient to effectively treat the patient.
The effective dose level of the administered compound for any particular subject will depend upon a variety of factors including: the type of condition being treated and the stage of the condition; the activity of the compound employed; the composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of sequestration of compounds; the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
One skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic dosage which would be required to treat applicable conditions. These will most often be determined on a case-by-case basis. By way of example only, an effective dosage may be expected to be in the range of about 0.0001 mg to about 1000mg per kg body weight per 24 hours;
typically, about 0.001mg to about 750mg per kg body weight per 24 hours; about 0.01mg to about 500mg per kg body weight per 24 hours; about 0.1mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 250mg per kg body weight per 24 hours; or about 1.0mg to about 250mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range of about 10mg to about 200mg per kg body weight per 24 hours.
Further, it will be apparent to those of ordinary skill in the art that the optimal quantity and spacing of individual dosages will principally be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the individual being treated. Suitable conditions can be determined by conventional techniques.
Formulations suitable for rectal administration are typically presented as unit dose suppositories.
These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
Formulations or compositions suitable for topical administration to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combination of two or more thereof. The active compound is generally present at a concentration of from 0.1 % to 0.5%
w/w, for example, from 0.5% to 2% w/w. Examples of such compositions include cosmetic skin creams.
Formulations suitable for inhalation may be delivered as a spray composition in the form of a solution, suspension or emulsion. The inhalation spray composition may further comprise a pharmaceutically acceptable propellant such as carbon dioxide or nitrous oxide or a hydrogen containing fluorocarbon such as 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof.
Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound as an optionally buffered aqueous solution of, for example, 0.1 M to 0.2 M concentration with respect to the said active compound. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6), 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. For example, suitable formulations may comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 M to 0.2 M
active ingredient.
The active compounds may be provided in the form of food stuffs, such as being added to, admixed into, coated, combined or otherwise added to a food stuff. The term food stuff is used in its widest possible sense and includes liquid formulations such as drinks including dairy products and other foods, such as health bars, desserts, etc. Food formulations containing compounds of the invention can be readily prepared according to standard practices.
According to the present invention, compounds and compositions may be administered either therapeutically or preventively. In a therapeutic application, compounds and compositions are administered to a patient already suffering from a disease or disorder or experiencing symptoms, in an amount sufficient to cure or at least partially arrest the disease or disorder, symptoms andlor any associated complications. The compound or composition should provide a quantity of the active compound sufficient to effectively treat the patient.
The effective dose level of the administered compound for any particular subject will depend upon a variety of factors including: the type of condition being treated and the stage of the condition; the activity of the compound employed; the composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of sequestration of compounds; the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
One skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic dosage which would be required to treat applicable conditions. These will most often be determined on a case-by-case basis. By way of example only, an effective dosage may be expected to be in the range of about 0.0001 mg to about 1000mg per kg body weight per 24 hours;
typically, about 0.001mg to about 750mg per kg body weight per 24 hours; about 0.01mg to about 500mg per kg body weight per 24 hours; about 0.1mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 250mg per kg body weight per 24 hours; or about 1.0mg to about 250mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range of about 10mg to about 200mg per kg body weight per 24 hours.
Further, it will be apparent to those of ordinary skill in the art that the optimal quantity and spacing of individual dosages will principally be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the individual being treated. Suitable conditions can be determined by conventional techniques.
It will also be apparent to those of ordinary skill in the art that the optimal course of treatment, such as, the number of doses of the composition given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
In accordance with the methods of the invention, isoflavonoid compounds or pharmaceutically acceptable derivatives prodrugs or salts thereof can be co-administered with other active agents that do not impair the desired action, or with agents that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, lipid lowering agents, platelet aggregation inhibitors, antithrombotic agents, calcium channel blockers, corticosteroids or antiviral compounds. The particular agent(s) used will depend on a number of factors and will typically be tailored to the disease or disorder to be treated. The co-administration of agents may be simultaneous or sequential. Simultaneous administration may be effected by the compounds being formulated in a single composition, or in separate compositions administered at the same or similar time. Sequential administration may be in any order as required.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
The present invention will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention.
Examples General Methods Compound I studies:
Cell lines and culture conditions. Established human EOC cell lines, A2780 and A27801CP70 (gifts from Dr. TC Hamilton) (Behrens et al, 1997) were propagated in RPMI plus 10%
fetal bovine serum (Gemini Bio-Products, Woodland, CA). Primary EOC cell lines were isolated from malignant ovarian ascites or explanted from ovarian tumors and cultured as previously described (Alvero et al, 2006).
Purity of the EOC cells was 100% as determined by immuno-staining for cytokeratin 7 antigen. All cell lines were grown at 37 C in a 5% CO2 atmosphere.
In accordance with the methods of the invention, isoflavonoid compounds or pharmaceutically acceptable derivatives prodrugs or salts thereof can be co-administered with other active agents that do not impair the desired action, or with agents that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, lipid lowering agents, platelet aggregation inhibitors, antithrombotic agents, calcium channel blockers, corticosteroids or antiviral compounds. The particular agent(s) used will depend on a number of factors and will typically be tailored to the disease or disorder to be treated. The co-administration of agents may be simultaneous or sequential. Simultaneous administration may be effected by the compounds being formulated in a single composition, or in separate compositions administered at the same or similar time. Sequential administration may be in any order as required.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
The present invention will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention.
Examples General Methods Compound I studies:
Cell lines and culture conditions. Established human EOC cell lines, A2780 and A27801CP70 (gifts from Dr. TC Hamilton) (Behrens et al, 1997) were propagated in RPMI plus 10%
fetal bovine serum (Gemini Bio-Products, Woodland, CA). Primary EOC cell lines were isolated from malignant ovarian ascites or explanted from ovarian tumors and cultured as previously described (Alvero et al, 2006).
Purity of the EOC cells was 100% as determined by immuno-staining for cytokeratin 7 antigen. All cell lines were grown at 37 C in a 5% CO2 atmosphere.
Cell viabil'-ty assay. Cell viability was determined as previously reported (Alvero et al., 2006). Briefly, cells (5 x 103) were plated in triplicate wells in a 100 pml volume per well of a 96-well microtiter plate (BD Biosciences/Pharmingen, San Diego, CA). The cells were grown to 70%
confluence and then incubated in reduced-serum phenol-depleted Opti-MEM medium (Invitrogen-GIBCO, Carlsbad, CA) for 4h prior to treatment. Compound 1(Novogen, Inc., NSW, Australia) was added to the medium from 10 mg/mi stock to give various final concentrations as described in the results section.
Following 24h treatment, cell viability was evaluated using the CeIlTiter 960 AQueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI) according to the manufacturer's instructions. Optical densities of the samples were measured at 490 nm using an automatic microplate reader (Model 550, Bio-Rad, Hurcules, CA). The values from the treated cells were compared with the values generated from the untreated control and reported as percent viability.
Each experiment was done in triplicate.
For experiments using the caspase inhibitor, Z-VAD-FMK (Sigma Aldrich, St.
Louis, MO), the inhibitor was added to the cultures 30 mins prior to treatment to yield a final concentration of 20 pM.
For experiments using the autophagy inhibitor, 3-methyladenine (Sigma Aldrich), the inhibitor was added 1 h prior to treatment to yield final concentration of 10 mM.
Flow cytometry with Hoechst and Propidium iodide staining. After treatment, ceils were trypsinized, washed twice with PBS, and resuspended at 1 x106 cells/ml. Cells were then stained with 5pg/mI
Hoechst 33342 (invitrogen-Molecular Probes, Carlsbad, CA) and 1 Ng/mi Propidium iodide (Sigma Aldrich) and incubated for 15 mins in the dark. Afterwards, data was acquired using BD LSR II
System and analyzed using FloJo FACS analysis software (Tree Star, Inc., Ashland, OR).
Protein preparation and cellular fractionation. After drug treatment, protein was extracted and measured as previously described (Alvero et al, 2006). For separation of the cytoplasmic and mitochondrial fractions, cell pellets were processed using the ApoAlertT^"
Cell Fractionation Kit (BD
Biosciences, San Jose, CA) according to the manufacturer's instructions. For separation of the cytoplasmic and nuclear fractions, pellets were processed using NE-PER Nuclear and Cytoplasmic Extraction (Pierce Biotechnology, Inc., Rockford, IL).
Caspase-3/7, -8, and -9 activity assay. Ten pg of protein in a 50 pI total volume was mixed with 50 {ui of equilibrated Caspase-Glo'o 3/7, 8, or 9 reagents (Promega). After incubating at room temperature for 1 h, luminescence was measured using TD 20/20 Luminometer (Turner Designs, Sunnyvale, CA). Blank values were subtracted and fold-increase in activity was determined in relation to the control non-treatment.
SDS-PAGE and Westem blots. Cell lysates (20 pg protein) were denatured in sample buffer (2.5%
SDS, 10% glycerol, 5% (i-mercapto-ethanol, 0.15 M Tris (pH=6.8) and 0.01%
bromophenol blue) and subjected to 12% SDS-PAGE as previously described (Kamsteeg et al, 2003).
The following antibodies and concentrations were used: mouse anti-XIAP (BD, 1:1,000), rabbit anti-MAP LC3 (1:200), rabbit anti-actin (Sigma, 1:10,000), rabbit anti-phosphorylated Akt (Cell Signaling, 1:1,000), rabbit anti-Akt (Cell Signaling, 1: 1000), rabbit anti-phosphorylated mTOR
(Cell Signaling, 1:1000), rabbit anti-mTOR (Cell Signaling, 1:1000), rabbit anti-cytochrome c (Clontech Laborato(es, Inc, Mountainview, CA, 1:100), rabbit anti-Omi (R&D Systems, Minneapolis, MN, 1:5000), rabbit anti-Bid (Cell Signaling, 1:1000), mouse anti-Bax (BD Pharmingen, 1:250), rabbit anti-VDAC (Sigma Aldrich, 1:2000), mouse anti-Bc12 (BD Pharmingen, 1:500), rabbit anti-AIF (Sigma Aldrich, 1:1000), rabbit anti-EndoG (Sigma Aldrich, 1:1000), mouse anti-topoisomerase I (BD Pharmingen, 1:10,000).
Proteins were visualized using enhanced chemiluminescence (Pierce, Rockford IL).
Analysis of phoshpo-proteins using xMAP technology. After treatment, cells were lysed and lysates were used to measure the phosphorylation status of 8 proteins using the Beadlyte 8-plex Multi-Pathway Signaling kit (Millipore, Billerica, MA) according to manufacturer's instructions. Data was acquired using the BioPlex System (BioRad, Hercules, CA).
Assay of mitochondrial depolarization using JG1. After treatment, cells were trypsinized and stained with JC-1 dye using the MitocaptureTM mitochondrial apoptosis detection kit (BioVision Research Products, Mountain View, CA) according to manufacturer's instruction. Data was acquired using BD
LSR II System and analyzed using BD FACSDiva SoftwareTM.
Immunoprecipitation. Beclin-1 was immunoprecipitated from the mitochondrial fraction of cells treated for lh with 10 pg/mi Compound 1 using the Catch and Release v2.0 Reversible Immunoprecipitation System (Millipore, Billerica, MA) and anti-rabbit Beclin-1 (Abcam, Cambridge, MA) according to manufacturer's instruction.
Mouse xenograft studies. The in vivo study as approved by the Yale University Institutional Animal Care & Use Committee. Cells (1 x106 cells) were resuspended in 200 p 1 total volume of 50% RPMI
and 50% BD Matrigel Matrix (BD Biosciences, Bedford, MA) and injected subcutaneously into the right flank of NCR nude mice. Intra-peritoneal therapy commenced eight days post-inoculation as follows: Paclitaxel 10 mg/kg qx3d, Carboplatin 40 mg/kg qx7d, and Compound 1 in 20% HPBCD, 100 mg/kg every day. Control groups received 20% HPBCD in PBS. Mice were treated and observed for 3 weeks. Tumor size was determined by caliper measurements and anti-tumor activity was analyzed with respect to maximal tumor inhibition (treated/control, T/C) as described previously (Kamsteeg et al, 2003).
Immunohistochemistry. Immunohistochemistry was performed as described previously (Kelly et al, 2006) using rabbit anti-EndoG (Lifespan Biosciences, Seattle,WA) at 1:100 dilution.
Compound 10 studies:
Cells. Human pancreatic cell lines HPAC, MIAPaCa-2 and PANC-1 were obtained from the ATCC.
(Manassas, VA). The cells were maintained in DMEM media with GIn and high glucose (Mediatech, Manassas, VA) with 10% fetal bovine serum (FBS, HyClone, Logan, UT) and pencillin/streptomycin.
Antibodies. Antibodies utilised in this study specific to p53 and, p21 were obtained from (Calbiochem, EMD, San Diego, CA), Caspase 9, XIAP, COX IV, Bc12 and Akt (Cell Signaling Technology, Danvers, MA), Caspase 2, Cytochrome c and Bid (BD Pharmingen, San Diego, CA).
GAPDH (RDI, Concord, MA) or R-actin (Sigma, St. Louis, MO) was used as a housekeeping gene to standardize the protein loading on the gels and blots.
Cells Viability. Cell viability was measured on 96 well plates using a MTS
assay (CeIlTiter 96 Aqueous One, Promega, Madison, WI) as described previously (Alvero et al., 2006).
FACS Analysis. Apoptosis was measured by FACS analysis using Annexin-V-FITC
and propidium iodide (PI) (Biovision, Mountain View, CA) as probes (Ahn et al., 2003).
Mitochondrial membrane potential was measured by FACS analysis using JC-1 (Biovision) as a probe (Ahn et al., 2003). Cell cycle was analyzed on ethanol-fixed, RNaseA-treated cells staining with PI. In each spectrum, 10,000 gated events were recorded and analyzed. with a FACSCalibur (BD
Biosciences. San Jose, CA). All experiments were done in triplicate, error bars represent one standard deviation. Caspase inhibitor I (zVAD-fmk) was obtained from Calbiochem.
Western blot analysis. Cells were seeded on 100 mm tissue culture plates and grown overnight to -90% confluence. Cells were then treated with the drug combinations for indicated time points.
After the final treatment step, the cells were lysed with 500 pL of a lysis buffer containing 1%
Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, 150 mM NaCI, 50 mM Tris-HCI pH7.5, 1 mM EDTA, 1 mM PMSF and protease inhibitors (Roche) on ice for 30 minutes. Cell lysates were harvested with a sterile cell scraper and centrifuged at 15,000 x g for 15 minutes to remove cell debris. Protein was assayed by the BCA method (Pierce) and 50 pg aliquots were separated on 12%,T, 2.6%C SDS-PAGE gels. Proteins were electrophoretically transferred to PVDF membranes (Immobilon P, Millipore, Billerica, MA) by the wet transfer method. These membranes were probed with specific antibodies and with anti-GAPDH which was used as the housekeeping gene to standardize the protein loading. The blots were developed on X-ray films using HRP-conjugated secondary antibodies (Southern Biotech, Birmingham, AL) and a chemiluminescent substrate (ECL, Amersham, NY).
Caspase Activity After 48h treatment with 10 pM Compound 10, HPAC, MIAPaCa-2 and PANC-1 cells were harvested by trypsinization and resuspended in DMEM media with 10%
FBS. The cells were incubated with caspase substrates for 1 h at 37 C, 5% C02, then probed with Annexin-V-Cy5 and sytox blue. Caspase +ve cells were gated as shown in the histograms and these cells are indicated on the Annexin-V-Cy5/ sytox blue spectra as blue cells. In situ caspase activity was assayed using fluorescent substrates. For Caspase 2, FITC-VDVAD-fmk (Biovision K182-100), for Caspase 3, FITC-DEVD-fmk (K183-100) and for Caspase 9, FITC-LEHD-fmk (K199-100) was used.
These substrates bind irreversibly to their respective activated caspases, and caspase activation was quantitated by flow cytometry. After 1 hr incubation at 37 C in 5% C02, the cells were washed with DPBS containing 5% FBS and resuspended in Annexin-V binding buffer containing Annexin-V-Cy5 (Biovision K103-3) and sytox blue (Invitrogen), a dye that binds necrotic cells. Caspase activation, apoptosis and necrosis were measured simultaneously using a violet, blue and red laser in a BD LSRII flow cytometer.
Example 1- Compound 1-induced cell death involves caspase-independent DNA
fragmentation Compound 1 has been found to decrease cell viability in a range of cancer cells including some EOC
cell lines (data not shown). Therefore, the inventors' first objective was to determine the effect of Compound I on a panel of primary cultures of EOC cells isolated from either ascites or tumor tissue, which include cultures that are paclitaxel-resistant (R182, R456) (Kelly et al, 2006). These cultures express high levels of the anti-apoptotic proteins XIAP and FLIP (16).
Paclitaxel-sensitive, as well as paclitaxel-resistant cultures showed a significant reduction in the percentage of viable cells after treatment with Compound 1 with G15o between 5 and 10 Ng/ml (Fig.1A).
To determine if the decrease in cell viability was due to apoptosis, cells were stained with Hoechst and Propidium Iodide (PI) and analyzed by flow cytometry. In addition, the activity of caspases-317, -8, and -9 was measured and the status of two anti-apoptotic molecules, XIAP
and phosphorylated Akt (p-Akt) determined. Compound 1 induced a significant increase in the incidence of fragmented DNA with 95% of cells staining positively for both Hoechst and PI after 24h (Fig. 1 B). However, in contrast to the increase in caspase activity observed after treatment with the known apoptotic inducer, Paclitaxel, no changes in caspase-3/7, -8, and -9 activities were observed after treatment with Compound 1 (Fig. 1 C). In addition, no change in the status XIAP (an anti-apoptotic protein) was seen (Fig. 2A). Interestingly, however, a strong down-regulation of p-Akt was observed as early as mins post-Compound I treatment (Fig. 2B).
DNA fragmentation in the absence of caspase activation suggests the involvement of a caspase-independent pathway. To conclusively show that Compound 1-induced cell death is caspase-10 independent, cells were treated with increasing concentrations of Compound 1 in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK. Inhibition of caspases had no impact on Compound 1-induced cell death (Fig. 2C). Taken together, these results suggest that Compound 1-induced cell death proceeds via a caspase-independent-, but possibly p-Akt dependent-pathway culminating in DNA fragmentation.
15 Example 2- Autophagy is not required for cell death induced by Compound I
Morphologically, Compound 1 treated EOC cells contained large intracellular vacuoles (Fig. 4B) that stained positively with acridine orange (data not shown) thereby suggesting that Compound 1 induces autophagic cell death. To determine whether the process of autophagy is involved, the levels of phosphorylated mTOR (p-mTOR), a major regulator of the autophagic pathway, and one of its targets, ribosomal p70 S6 kinase (p-S6k) were determined. In addition, the levels of the autophagic marker LC3-II were determined. Western blot analyses showed that p-mTOR and p-S6k were down-regulated 15 mins post-Compound 1 treatment (Fig. 3A) followed by a significant increase in the levels of LC3-II (Fig. 3B) confirming the activation of the autophagic pathway.
To determine if the process of autophagy is the primary mechanism of Compound 1-induced cell death, cells were treated with Compound 1 (10 Ng/mI) in the presence or absence of the well-characterized autophagy inhibitor, 3-methyladenine (3-MA), which inhibits the earliest step in the autophagosome formation (Seglen and Bohley, 1992). Cell viability studies employing 3 MA (10 pM) showed that the compound is not able to inhibit Compound 1-induced cell death (Fig. 2C).
These data suggest that while some characteristics of autophagy were observed, it is not the primary mechanism of cell death induced by Compound 1.
confluence and then incubated in reduced-serum phenol-depleted Opti-MEM medium (Invitrogen-GIBCO, Carlsbad, CA) for 4h prior to treatment. Compound 1(Novogen, Inc., NSW, Australia) was added to the medium from 10 mg/mi stock to give various final concentrations as described in the results section.
Following 24h treatment, cell viability was evaluated using the CeIlTiter 960 AQueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI) according to the manufacturer's instructions. Optical densities of the samples were measured at 490 nm using an automatic microplate reader (Model 550, Bio-Rad, Hurcules, CA). The values from the treated cells were compared with the values generated from the untreated control and reported as percent viability.
Each experiment was done in triplicate.
For experiments using the caspase inhibitor, Z-VAD-FMK (Sigma Aldrich, St.
Louis, MO), the inhibitor was added to the cultures 30 mins prior to treatment to yield a final concentration of 20 pM.
For experiments using the autophagy inhibitor, 3-methyladenine (Sigma Aldrich), the inhibitor was added 1 h prior to treatment to yield final concentration of 10 mM.
Flow cytometry with Hoechst and Propidium iodide staining. After treatment, ceils were trypsinized, washed twice with PBS, and resuspended at 1 x106 cells/ml. Cells were then stained with 5pg/mI
Hoechst 33342 (invitrogen-Molecular Probes, Carlsbad, CA) and 1 Ng/mi Propidium iodide (Sigma Aldrich) and incubated for 15 mins in the dark. Afterwards, data was acquired using BD LSR II
System and analyzed using FloJo FACS analysis software (Tree Star, Inc., Ashland, OR).
Protein preparation and cellular fractionation. After drug treatment, protein was extracted and measured as previously described (Alvero et al, 2006). For separation of the cytoplasmic and mitochondrial fractions, cell pellets were processed using the ApoAlertT^"
Cell Fractionation Kit (BD
Biosciences, San Jose, CA) according to the manufacturer's instructions. For separation of the cytoplasmic and nuclear fractions, pellets were processed using NE-PER Nuclear and Cytoplasmic Extraction (Pierce Biotechnology, Inc., Rockford, IL).
Caspase-3/7, -8, and -9 activity assay. Ten pg of protein in a 50 pI total volume was mixed with 50 {ui of equilibrated Caspase-Glo'o 3/7, 8, or 9 reagents (Promega). After incubating at room temperature for 1 h, luminescence was measured using TD 20/20 Luminometer (Turner Designs, Sunnyvale, CA). Blank values were subtracted and fold-increase in activity was determined in relation to the control non-treatment.
SDS-PAGE and Westem blots. Cell lysates (20 pg protein) were denatured in sample buffer (2.5%
SDS, 10% glycerol, 5% (i-mercapto-ethanol, 0.15 M Tris (pH=6.8) and 0.01%
bromophenol blue) and subjected to 12% SDS-PAGE as previously described (Kamsteeg et al, 2003).
The following antibodies and concentrations were used: mouse anti-XIAP (BD, 1:1,000), rabbit anti-MAP LC3 (1:200), rabbit anti-actin (Sigma, 1:10,000), rabbit anti-phosphorylated Akt (Cell Signaling, 1:1,000), rabbit anti-Akt (Cell Signaling, 1: 1000), rabbit anti-phosphorylated mTOR
(Cell Signaling, 1:1000), rabbit anti-mTOR (Cell Signaling, 1:1000), rabbit anti-cytochrome c (Clontech Laborato(es, Inc, Mountainview, CA, 1:100), rabbit anti-Omi (R&D Systems, Minneapolis, MN, 1:5000), rabbit anti-Bid (Cell Signaling, 1:1000), mouse anti-Bax (BD Pharmingen, 1:250), rabbit anti-VDAC (Sigma Aldrich, 1:2000), mouse anti-Bc12 (BD Pharmingen, 1:500), rabbit anti-AIF (Sigma Aldrich, 1:1000), rabbit anti-EndoG (Sigma Aldrich, 1:1000), mouse anti-topoisomerase I (BD Pharmingen, 1:10,000).
Proteins were visualized using enhanced chemiluminescence (Pierce, Rockford IL).
Analysis of phoshpo-proteins using xMAP technology. After treatment, cells were lysed and lysates were used to measure the phosphorylation status of 8 proteins using the Beadlyte 8-plex Multi-Pathway Signaling kit (Millipore, Billerica, MA) according to manufacturer's instructions. Data was acquired using the BioPlex System (BioRad, Hercules, CA).
Assay of mitochondrial depolarization using JG1. After treatment, cells were trypsinized and stained with JC-1 dye using the MitocaptureTM mitochondrial apoptosis detection kit (BioVision Research Products, Mountain View, CA) according to manufacturer's instruction. Data was acquired using BD
LSR II System and analyzed using BD FACSDiva SoftwareTM.
Immunoprecipitation. Beclin-1 was immunoprecipitated from the mitochondrial fraction of cells treated for lh with 10 pg/mi Compound 1 using the Catch and Release v2.0 Reversible Immunoprecipitation System (Millipore, Billerica, MA) and anti-rabbit Beclin-1 (Abcam, Cambridge, MA) according to manufacturer's instruction.
Mouse xenograft studies. The in vivo study as approved by the Yale University Institutional Animal Care & Use Committee. Cells (1 x106 cells) were resuspended in 200 p 1 total volume of 50% RPMI
and 50% BD Matrigel Matrix (BD Biosciences, Bedford, MA) and injected subcutaneously into the right flank of NCR nude mice. Intra-peritoneal therapy commenced eight days post-inoculation as follows: Paclitaxel 10 mg/kg qx3d, Carboplatin 40 mg/kg qx7d, and Compound 1 in 20% HPBCD, 100 mg/kg every day. Control groups received 20% HPBCD in PBS. Mice were treated and observed for 3 weeks. Tumor size was determined by caliper measurements and anti-tumor activity was analyzed with respect to maximal tumor inhibition (treated/control, T/C) as described previously (Kamsteeg et al, 2003).
Immunohistochemistry. Immunohistochemistry was performed as described previously (Kelly et al, 2006) using rabbit anti-EndoG (Lifespan Biosciences, Seattle,WA) at 1:100 dilution.
Compound 10 studies:
Cells. Human pancreatic cell lines HPAC, MIAPaCa-2 and PANC-1 were obtained from the ATCC.
(Manassas, VA). The cells were maintained in DMEM media with GIn and high glucose (Mediatech, Manassas, VA) with 10% fetal bovine serum (FBS, HyClone, Logan, UT) and pencillin/streptomycin.
Antibodies. Antibodies utilised in this study specific to p53 and, p21 were obtained from (Calbiochem, EMD, San Diego, CA), Caspase 9, XIAP, COX IV, Bc12 and Akt (Cell Signaling Technology, Danvers, MA), Caspase 2, Cytochrome c and Bid (BD Pharmingen, San Diego, CA).
GAPDH (RDI, Concord, MA) or R-actin (Sigma, St. Louis, MO) was used as a housekeeping gene to standardize the protein loading on the gels and blots.
Cells Viability. Cell viability was measured on 96 well plates using a MTS
assay (CeIlTiter 96 Aqueous One, Promega, Madison, WI) as described previously (Alvero et al., 2006).
FACS Analysis. Apoptosis was measured by FACS analysis using Annexin-V-FITC
and propidium iodide (PI) (Biovision, Mountain View, CA) as probes (Ahn et al., 2003).
Mitochondrial membrane potential was measured by FACS analysis using JC-1 (Biovision) as a probe (Ahn et al., 2003). Cell cycle was analyzed on ethanol-fixed, RNaseA-treated cells staining with PI. In each spectrum, 10,000 gated events were recorded and analyzed. with a FACSCalibur (BD
Biosciences. San Jose, CA). All experiments were done in triplicate, error bars represent one standard deviation. Caspase inhibitor I (zVAD-fmk) was obtained from Calbiochem.
Western blot analysis. Cells were seeded on 100 mm tissue culture plates and grown overnight to -90% confluence. Cells were then treated with the drug combinations for indicated time points.
After the final treatment step, the cells were lysed with 500 pL of a lysis buffer containing 1%
Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, 150 mM NaCI, 50 mM Tris-HCI pH7.5, 1 mM EDTA, 1 mM PMSF and protease inhibitors (Roche) on ice for 30 minutes. Cell lysates were harvested with a sterile cell scraper and centrifuged at 15,000 x g for 15 minutes to remove cell debris. Protein was assayed by the BCA method (Pierce) and 50 pg aliquots were separated on 12%,T, 2.6%C SDS-PAGE gels. Proteins were electrophoretically transferred to PVDF membranes (Immobilon P, Millipore, Billerica, MA) by the wet transfer method. These membranes were probed with specific antibodies and with anti-GAPDH which was used as the housekeeping gene to standardize the protein loading. The blots were developed on X-ray films using HRP-conjugated secondary antibodies (Southern Biotech, Birmingham, AL) and a chemiluminescent substrate (ECL, Amersham, NY).
Caspase Activity After 48h treatment with 10 pM Compound 10, HPAC, MIAPaCa-2 and PANC-1 cells were harvested by trypsinization and resuspended in DMEM media with 10%
FBS. The cells were incubated with caspase substrates for 1 h at 37 C, 5% C02, then probed with Annexin-V-Cy5 and sytox blue. Caspase +ve cells were gated as shown in the histograms and these cells are indicated on the Annexin-V-Cy5/ sytox blue spectra as blue cells. In situ caspase activity was assayed using fluorescent substrates. For Caspase 2, FITC-VDVAD-fmk (Biovision K182-100), for Caspase 3, FITC-DEVD-fmk (K183-100) and for Caspase 9, FITC-LEHD-fmk (K199-100) was used.
These substrates bind irreversibly to their respective activated caspases, and caspase activation was quantitated by flow cytometry. After 1 hr incubation at 37 C in 5% C02, the cells were washed with DPBS containing 5% FBS and resuspended in Annexin-V binding buffer containing Annexin-V-Cy5 (Biovision K103-3) and sytox blue (Invitrogen), a dye that binds necrotic cells. Caspase activation, apoptosis and necrosis were measured simultaneously using a violet, blue and red laser in a BD LSRII flow cytometer.
Example 1- Compound 1-induced cell death involves caspase-independent DNA
fragmentation Compound 1 has been found to decrease cell viability in a range of cancer cells including some EOC
cell lines (data not shown). Therefore, the inventors' first objective was to determine the effect of Compound I on a panel of primary cultures of EOC cells isolated from either ascites or tumor tissue, which include cultures that are paclitaxel-resistant (R182, R456) (Kelly et al, 2006). These cultures express high levels of the anti-apoptotic proteins XIAP and FLIP (16).
Paclitaxel-sensitive, as well as paclitaxel-resistant cultures showed a significant reduction in the percentage of viable cells after treatment with Compound 1 with G15o between 5 and 10 Ng/ml (Fig.1A).
To determine if the decrease in cell viability was due to apoptosis, cells were stained with Hoechst and Propidium Iodide (PI) and analyzed by flow cytometry. In addition, the activity of caspases-317, -8, and -9 was measured and the status of two anti-apoptotic molecules, XIAP
and phosphorylated Akt (p-Akt) determined. Compound 1 induced a significant increase in the incidence of fragmented DNA with 95% of cells staining positively for both Hoechst and PI after 24h (Fig. 1 B). However, in contrast to the increase in caspase activity observed after treatment with the known apoptotic inducer, Paclitaxel, no changes in caspase-3/7, -8, and -9 activities were observed after treatment with Compound 1 (Fig. 1 C). In addition, no change in the status XIAP (an anti-apoptotic protein) was seen (Fig. 2A). Interestingly, however, a strong down-regulation of p-Akt was observed as early as mins post-Compound I treatment (Fig. 2B).
DNA fragmentation in the absence of caspase activation suggests the involvement of a caspase-independent pathway. To conclusively show that Compound 1-induced cell death is caspase-10 independent, cells were treated with increasing concentrations of Compound 1 in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK. Inhibition of caspases had no impact on Compound 1-induced cell death (Fig. 2C). Taken together, these results suggest that Compound 1-induced cell death proceeds via a caspase-independent-, but possibly p-Akt dependent-pathway culminating in DNA fragmentation.
15 Example 2- Autophagy is not required for cell death induced by Compound I
Morphologically, Compound 1 treated EOC cells contained large intracellular vacuoles (Fig. 4B) that stained positively with acridine orange (data not shown) thereby suggesting that Compound 1 induces autophagic cell death. To determine whether the process of autophagy is involved, the levels of phosphorylated mTOR (p-mTOR), a major regulator of the autophagic pathway, and one of its targets, ribosomal p70 S6 kinase (p-S6k) were determined. In addition, the levels of the autophagic marker LC3-II were determined. Western blot analyses showed that p-mTOR and p-S6k were down-regulated 15 mins post-Compound 1 treatment (Fig. 3A) followed by a significant increase in the levels of LC3-II (Fig. 3B) confirming the activation of the autophagic pathway.
To determine if the process of autophagy is the primary mechanism of Compound 1-induced cell death, cells were treated with Compound 1 (10 Ng/mI) in the presence or absence of the well-characterized autophagy inhibitor, 3-methyladenine (3-MA), which inhibits the earliest step in the autophagosome formation (Seglen and Bohley, 1992). Cell viability studies employing 3 MA (10 pM) showed that the compound is not able to inhibit Compound 1-induced cell death (Fig. 2C).
These data suggest that while some characteristics of autophagy were observed, it is not the primary mechanism of cell death induced by Compound 1.
To determine if Compound 1 affects specific survival pathways, a panel of phospho-proteins in cells incubated in the presence or absence of 10 pg/ml of Compound 1 was evaluated.
As shown in Figure 3C, of the 8 phospho-proteins tested, Compound 1 down-regulates only p-S6k, confirming the western blot results, and had minimal or no effect on plxB, pSTAT3, and p38.
Up-regulation of ERK, pJNK, pSTAT5a/b, and pCREB was also observed, which probably represents a compensatory response. These results suggest a specific effect of Compound 1 on the mTOR
pathway.
Example 3 - Mitochondrial depolarization, mitochondrial translocation and nuclear translocation Control and treated cells were stained with JC-1 dye, a cationic fluorescent dye that stains intact mitochondria red and shifts to green during mitochondrial depolarization. When compared to vehicle control, immunofluourescent images of Compound 1 treated cells were mostly green in appearance (Fig. 4). This observed shift in JC-1 spectrum from red to green in Compound 1 treated cells confirms that Compound 1 is able to induce mitochondrial depolarization. This shift was confirmed by flow cytometry, which showed 30% (1h) and 50% (4h) of cells having depolarized mitochondria post-Compound 1 treatment (Fig 5).
The stability of the mitochondrial membrane is partly controlled by the Bc12 family of proteins characterized by their conserved BH domains. Bid and Bax are cytoplasmic proteins that translocate to the mitochondria to initiate depolarization. In contrast, Bc12 is a resident mitochondrial protein that stabilizes the membrane. Treatment with Compound 1 induces mitochondrial translocation of Bax 2h post-treatment but does not induce the activation of Bid (Fig. 6A). Given that Bax translocation, normally one of the first mediators of mitochondrial membrane destabilization, occurs after the onset of Compound 1-induced mitochondrial depolarization, an alternative mechanism must be responsible for the initiation of mitochondrial instability. Beclin-1 is a molecule best described in relation to its role in autophagy. In addition, Beclin-1 was recently shown to have a BH
domain, therefore making it a justifiable member of the Bc12 family of proteins. Analysis of Beclin-1 mRNA by RT-PCR and Beclin-1 protein levels from whole cell Iysates showed no changes in Beclin-1 message or protein expression after Compound 1 treatment (data not shown). However, analysis of mitochondrial fractions showed that Beclin-1 translocates to the mitochondria as early as lh post-Compound 1 treatment (Fig. 6A), which correlates with the onset of mitochondrial depolarization.
As shown in Figure 3C, of the 8 phospho-proteins tested, Compound 1 down-regulates only p-S6k, confirming the western blot results, and had minimal or no effect on plxB, pSTAT3, and p38.
Up-regulation of ERK, pJNK, pSTAT5a/b, and pCREB was also observed, which probably represents a compensatory response. These results suggest a specific effect of Compound 1 on the mTOR
pathway.
Example 3 - Mitochondrial depolarization, mitochondrial translocation and nuclear translocation Control and treated cells were stained with JC-1 dye, a cationic fluorescent dye that stains intact mitochondria red and shifts to green during mitochondrial depolarization. When compared to vehicle control, immunofluourescent images of Compound 1 treated cells were mostly green in appearance (Fig. 4). This observed shift in JC-1 spectrum from red to green in Compound 1 treated cells confirms that Compound 1 is able to induce mitochondrial depolarization. This shift was confirmed by flow cytometry, which showed 30% (1h) and 50% (4h) of cells having depolarized mitochondria post-Compound 1 treatment (Fig 5).
The stability of the mitochondrial membrane is partly controlled by the Bc12 family of proteins characterized by their conserved BH domains. Bid and Bax are cytoplasmic proteins that translocate to the mitochondria to initiate depolarization. In contrast, Bc12 is a resident mitochondrial protein that stabilizes the membrane. Treatment with Compound 1 induces mitochondrial translocation of Bax 2h post-treatment but does not induce the activation of Bid (Fig. 6A). Given that Bax translocation, normally one of the first mediators of mitochondrial membrane destabilization, occurs after the onset of Compound 1-induced mitochondrial depolarization, an alternative mechanism must be responsible for the initiation of mitochondrial instability. Beclin-1 is a molecule best described in relation to its role in autophagy. In addition, Beclin-1 was recently shown to have a BH
domain, therefore making it a justifiable member of the Bc12 family of proteins. Analysis of Beclin-1 mRNA by RT-PCR and Beclin-1 protein levels from whole cell Iysates showed no changes in Beclin-1 message or protein expression after Compound 1 treatment (data not shown). However, analysis of mitochondrial fractions showed that Beclin-1 translocates to the mitochondria as early as lh post-Compound 1 treatment (Fig. 6A), which correlates with the onset of mitochondrial depolarization.
Apart from its role in the initiation of autophagy where it associates with Class III PI-3 kinase, it has been demonstrated that the BH3 domain of Beclin-1 is able to interact with both BCI2 and Bc6. In lieu of this, the inventors hypothesized that Beclin-1 mitochondrial translocation can lead to its interaction with BCI2 and therefore interfere with the ability of BCI2 to stabilize mitochondria. To show this association, Beclin-1 was immunoprecipitated from the mitochondrial fraction of untreated cells or cells treated with Compound 1 for 1 hr. The presence of Bc12 and Bak in the immunecomplex was then determined by westem blotting. Higher levels of Bc12 in complex with Beclin-1 were observed after Compound 1 treatment compared to the no treatment control (Fig. 6B) demonstrating that Compound 1-induced Beclin-1 mitochondrial translocation leads to Beclin1-Bc12 interaction. Bak was not observed in the complex suggesting that this is a specific interaction between Beclin-1 and Bc12.
These findings imply that Beclin-1 may have the ability to initiate mitochondrial depolarization by translocating to the mitochondria where it binds to and inactivates Bc12, potentially in a similar manner as those described for the Bid-Bak or Bid-Bax interaction.
Mitochondrial nucleases represent a family of proteins that, once released from the mitochondria, can translocate to the nucleus and induce DNA fragmentation. The observation that Compound 1 is able to induce mitochondrial depolarization suggests that a mitochondrial nuciease may be responsible for the observed DNA fragmentation. Thus, westem blot analysis was used to quantify the level of the mitochondrial nucleases, apoptosis-inducing factor (AIF) and endonuclease G
(EndoG), in nuclear fractions of Compound 1-treated cells, An increase in the level of nuclear EndoG, but not AIF, was observed after Compound 1 treatment (Fig. 7) suggesting that EndoG is released from the mitochondria and translocates to the nucleus where it catalyses DNA
fragmentation.
Example 4- Anti-tumor activity of Compound I on a chemo-resistant EOC
xenograft model The inventors then assessed the in vivo anti-tumor activity of Compound 1. A
nude mouse EOC
xenograft model was established using EOC cells isolated from malignant ovarian cancer ascites.
The anti-tumor activity of Compound 1 was compared with that of carboplatin and paclitaxel as described above. Compound 1 induced a significant decrease in tumor proliferation kinetics (Fig.
8A), and final tumor size and volume in a dose-dependent manner (Figs. 8B and 8C), compared to carboplatin and paclitaxel (Figs. 8A and 8B). T/C values were 30%, 58%, and 58% for Compound 1, carboplatin, and paclitaxel, respectively. No toxic side effects were noted in the Compound 1-treated groups, whereas mice in the carboplatin group exhibited severe weight loss and cachexia.
These findings imply that Beclin-1 may have the ability to initiate mitochondrial depolarization by translocating to the mitochondria where it binds to and inactivates Bc12, potentially in a similar manner as those described for the Bid-Bak or Bid-Bax interaction.
Mitochondrial nucleases represent a family of proteins that, once released from the mitochondria, can translocate to the nucleus and induce DNA fragmentation. The observation that Compound 1 is able to induce mitochondrial depolarization suggests that a mitochondrial nuciease may be responsible for the observed DNA fragmentation. Thus, westem blot analysis was used to quantify the level of the mitochondrial nucleases, apoptosis-inducing factor (AIF) and endonuclease G
(EndoG), in nuclear fractions of Compound 1-treated cells, An increase in the level of nuclear EndoG, but not AIF, was observed after Compound 1 treatment (Fig. 7) suggesting that EndoG is released from the mitochondria and translocates to the nucleus where it catalyses DNA
fragmentation.
Example 4- Anti-tumor activity of Compound I on a chemo-resistant EOC
xenograft model The inventors then assessed the in vivo anti-tumor activity of Compound 1. A
nude mouse EOC
xenograft model was established using EOC cells isolated from malignant ovarian cancer ascites.
The anti-tumor activity of Compound 1 was compared with that of carboplatin and paclitaxel as described above. Compound 1 induced a significant decrease in tumor proliferation kinetics (Fig.
8A), and final tumor size and volume in a dose-dependent manner (Figs. 8B and 8C), compared to carboplatin and paclitaxel (Figs. 8A and 8B). T/C values were 30%, 58%, and 58% for Compound 1, carboplatin, and paclitaxel, respectively. No toxic side effects were noted in the Compound 1-treated groups, whereas mice in the carboplatin group exhibited severe weight loss and cachexia.
Finally, to demonstrate that the in vivo anti-tumor activity of Compound 1 parallels the observed mechanisms in vitro, tumors were lysed and the level of p-S6k was determined by western blot analysis and paraffin-embedded sections of mouse tumors were immunostained for EndoG. As shown in Figure 8D, tumors taken from animals treated with Compound 1 had a significant decrease on p-S6k, compared to the vehicle control (Fig 8D). In addition, the nuclear localization of EndoG in tumors taken from animals treated with Compound 1 was observed, while tumors from control animals had only cytoplasmic staining (Fig. 8E).
Example 5- Caspase-independent apoptosis induced by Compound 10 To determine whether Compound 10 was able to induce apoptosis in pancreatic cancer cells, the inventors conducted dose-escalating studies over 48 hr exposure and employed FACS analysis on Annexin-V-FITC/Pl stained cells. In all cell types analysed (HPAC, MIAPaCa-2 and PANC-1), Compound 10 induced apoptosis in a dose-dependent fashion (Fig. 9). Very little necrosis was observed.
HPAC cells are resistant to TRAIL and sensitive to FasL-dependent apoptosis while MIAPaCa-2 cells are sensitive to TRAIL-dependent apoptosis and resistant to FasL-dependent apoptosis, both of which are caspase-dependent apoptosis pathways. As a result, Fas-activating antibody CH11 (Upstate) and TRAIL were used as positive controls respectively in these cell types. In HPAC cells, pre-treatment of cells with 10 pM caspase inhibitor I (zVAD-fmk) for 1 hr resulted in an inhibition of Fas-dependent necrosis while the same pre-treatment inhibited Compound 10-dependent necrosis but did not inhibit Compound 10-induced apoptosis (Fig. 9A). In MIAPaCa-2 cells, pre-treatment of cells with zVAD-fmk resulted in an inhibition of TRAIL-dependent apoptosis while the same pre-treatment inhibited Compound 10-dependent necrosis and apparently enhanced Compound 10-induced apoptosis, perhaps as a result of the cells being blocked from advancing to necrosis (Fig.
9B). These results show that a large component of the apoptotic effect induced by Compound 10 uses caspase-independent pathways in pancreatic cancer cells while the Compound 10-induced necrotic pathways are caspase-dependent.
Caspase activation, apoptosis and necrosis were measured simultaneously in untreated and Compound 10-treated pancreatic cancer cells by flow cytometry. After 48 hrs, Compound 10 activated caspase 2, 3 and 9 in MIAPaCa-2 and PANC-1 cells (Fig. 10). Caspase positive cells were also Annexin-V-Cy5 positive showing that the Compound 10-induced caspase activation was in cells undergoing apoptosis. Approximately 60% of Compound 10-treated, caspase positive cells were Annexin-V positive and sytox blue negative indicating that they were in the early stages of apoptosis.
Approximately 30% of the caspase positive cells bound both Annexin-V-Cy5 and sytox blue indicating that these cells were entering the later stages of aspoptosis. Less than 5% of the Compound 10-induced, caspase positive cells were sytox blue positive and Annexin-V negative indicating that caspases contibute little to Compound 10-dependent necrosis.
With the exception of caspase-3 which was modestly induced in treated HPAC cells, neither caspase 2 or caspase 9 were induced in this cell line using the conditions employed (Fig. 10). At a higher concentration, (30 pM) Compound 10 activated caspase 9 but not caspase 2 in HPAC cells (data not shown). These data suggest that caspase-independent mechanisms of apoptosis are activated in Compound 10 treated HPAC cells.
Western blot analysis showed that full-length Caspase 2 (48Kd) was cleaved in MIAPaCa-2 cells by exposure to 10 pM Compound 10 (Fig. 11A). In contrast, Caspase 2 was cleaved to a lesser extent by Compound 10 in HPAC cells (Fig. 11A). Over the course of the time-course experiment, Compound 10 induced an initial drop in cleaved caspase 9(17kd) followed by an increase after 16 hr in both cell types (Fig. 11 B). Treatment with Compound 10 did not cause significant cleavage of Caspase 3 in MIAPaCa-2 and HPAC cells. Longer exposure of the same blots showed minor cleavage of Caspase 3 in HPAC but not in MIAPaCa-2 cells (data not shown).
Taken together, these experiments suggest that Compound 10 is affecting both caspase activation and synthesis.
Example 6 - Effect of Compound 10 and on in vitro mitochondrial potential and cell cycle progression In all cell lines tested (see Example 5), Compound 10 depolarized the mitochondria of these cells in a dose-dependent manner following 48 hrs of treatment showing that the intrinsic pathway of apoptosis has been activated (Fig 12).
In all three cell lines Compound 10 arrested the cell cycle in G2/M phase to varying degrees, with a loss of Go/Gi and an increase in sub-Go/Gi phase (Fig 13). The timing of Compound 10 induced G2/M arrest was different for each cell line. PANC-1 was arrested in G2/M some 4-24 hr post Compound 10 treatment and remained in arrest for at least 48 hrs. MIAPaCa-2 cells entered G2/M
arrest some 24-48 hr post Compound 10 treatment. Accompanying the arrest was a corresponding decrease in the Go/Gi cell population. The G2/M arrest observed in HPAC cells in response to Compound 10 was less pronounced and was accompanied with an arrest in Go/Gi.
However, the arrest induced would appear to be transient (Fig. 13).
Previous studies on OEC cells had shown that the caspase 3 inhibitor XIAP is significantly reduced by phenoxodiol and that this isoflavanoid stimulates auto-degradation of this BIRC family member 5(Alvero et al., 2006). In both HPAC and MIAPaCa-2 cells, Compound 10 reduced the level of XIAP
(Fig 1 1A), however XIAP degradation was more pronounced in MIAPaCa-2 cells.
Reduction of XIAP
is likely to remove a block on caspase 3 activation (Deveraux et al. 1997).
Importantly, total Akt is also reduced at an early timepoint (4hr) suggesting that total Akt removal accompanied by XIAP
degradation are two of the earliest events in Compound 10 mechanism of action.
Reduction in Akt expression would also impact on the expression of XIAP (Alvero et al., 2006 and Alvero et al., 2008).
Example 7- Effect of Compound 10 on Bc12 family member stoichiometry As noted in Example 6, Compound 10 induced mitochondrial depolarization. The inventors therefore investigated whether its action may be involved in altering the stoichiometry of pro-apoptotic (Bid, Bak, Bax) and anti-apoptotic (Bc12, BcIxL) Bc12 family members. Levels of Bc12 were lowered by Compound 10 treatment in MIAPaCa-2 and HPAC cells (Fig. 11A). Treatment with either Compound 10 induced Bid cleavage over time in MIAPaCa-2 cells (Fig 11A) while there appeared to be a transitory increase in Bid cleavage by Compound 10 in HPAC cells (Fig.11A).
The cell cycle is controlled by cyclin-dependent kinases, which in turn are regulated by p21, usually in a p53-dependent pathway. Most pancreatic cancers have mutant p53, which arrests p53-dependent transcription. HPAC cells are unusual in having a wild type p53, while MIAPaCa-2 and PANC-1 have R248W and R273H mutations in p53. These mutations are in loop 3 of p53 and affect the ability of p53 to bind DNA. The basal level of p53 protein is 94x higher in MIAPaCa-2 cells than HPAC cells (data not shown). Expression of p53 in MIAPaCa-2 cells was unaffected by Compound 10 (Fig. 1113) but was elevated by 48 hr in HPAC cells (Fig.11B). p21 is vanishingly low in MIAPaCa-2 cells and is elevated by Compound 10 (Fig. 11 B), while p21 is abundant in HPAC cells and is essentially unchanged by Compound 10 (Fig. 11 B).
Example 8-Anti-tumor activity of Compound 10 alone and in combination with gemcitabine For xenograft studies, five week old male Balb/c nude mice were maintained on an isoflavone-free diet to remove background isoflavone levels contributed by standard feed. On the day of inoculation a suspension of MIAPaCa2 or HPAC cells was prepared in DMEM (-FBS), chilled on ice and then an equal volume of matrigel (BD) was added. Mice were inoculated subcutaneously with 3 x 106 MIAPaCa2 or HPAC cells bilaterally (midway between the axillary and inguinal region) along the dorsal surface, ensuring that cells to be injected were growing at mid-end log phase. Tumor growth was monitored over 10-15 days. Compound 10 was given orally by gavage in 1%
carboxy methyl cellulose (CMC) as a vehicle. Gemcitabine was injected intraperiponeally in PBS. In combination groups animals were first dosed with Compound 10 and then dosed with gemcitabine using the respective administration schedule, dosage and route of delivery stated.
In the HPAC model of pancreatic cancer, animals dosed with the Compound 10 and gemcitabine combination at 50 and 4 mg/kg respectively displayed significantly reduced rates of tumor proliferation and terminal tumor burden (% T/C = 38) in comparison to the respective single agent controls (data not shown). Further, those animals receiving the combination Compound 10 and gemcitabine at dosages half that of the single agent controls (25 mg/kg Compound 10 and 2 mg/kg gemcitabine) also had significantly reduced tumor proliferation kinetics and reduced terminal tumor burden (%T/C = 47.8) when compared to monotherapy controls. The effectiveness of both Compound 10:gemcitabine dosage combinations was further demonstrated by the observation that tumors on animals dosed with either combination proliferated at significantly reduced rates in a dose responsive manner when compared to the respective monotherapy controls (data not shown).
Together these data indicate that Compound 10 and gemcitabine when dosed in combination act synergistically in reducing overall tumor burden using the HPAC pancreatic cancer tumor model.
In the MIAPaCa-2 model of pancreatic cancer, when compared to vehicle control, orally administered Compound 10 (100 mg/kg, qdX12) retarded the rate of tumor proliferation, at a level similar to that of gemcitabine (20 mg/kg, q3dx4). Animals dose dosed with both Compound 10 and gemcitabine at 100 and 20 mg/kg respectively had significantly reduced tumor growth and terminal tumor burden (%T/C = 51) when compared to vehicle and single agent controls.
The observed mean terminal tumor burden for the combination was markedly below that of the respective single agent controls (100 mg/kg Compound 10, T/C = 94%; for 20 mg/kg gemcitabine, T/C =
79%. These data suggest that when dosed in combination, Compound 10 and gemcitabine may act synergistically to reduce overall tumor burden using the MIAPaCa-2 pancreatic cancer xenografts.
In those animals receiving high and low dose combinations of gemcitabine and Compound 10, all markers of renal and hepatic function were comparable to that of control animals as were white blood cell and red blood cell counts (data not shown). Histopathological analysis of vital organs revealed no abnormalities that could be attributed to drug toxicity (not shown). These data demonstrate that Compound 10 does not exacerbate gemcitabine toxicity with respect to the parameters measured and can be used safely in combination with gemcitabine at the dosages employed.
References Ahn E-Y, et al., Am J. Pathol. 2003 163: 2053-2063.
Alvero AB, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells, Cancer2006 Feb 1; 106 (3): 599-608.
Alvero AB, et al. Anti-tumour activity of phenoxodiol: From bench to Clinic.
Future Oncology 2008 (accepted).
Behrens BC, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987 Jan 15; 47 (2):
414-418.
Deveraux QL, et aI. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997 388: 300-304.
Hail Jr N, et al. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis 2006;11: 889-904.
Hay N and Sonenberg N. Upstream and downstream of mTOR. Joumal Genes & Dev 2004; 18:
1926-1945.
Kamsteeg M, et al. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003 May 1; 22 (17): 2611-2620.
Kelly MG, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006 Apr 1; 66 (7): 3859-3868.
Example 5- Caspase-independent apoptosis induced by Compound 10 To determine whether Compound 10 was able to induce apoptosis in pancreatic cancer cells, the inventors conducted dose-escalating studies over 48 hr exposure and employed FACS analysis on Annexin-V-FITC/Pl stained cells. In all cell types analysed (HPAC, MIAPaCa-2 and PANC-1), Compound 10 induced apoptosis in a dose-dependent fashion (Fig. 9). Very little necrosis was observed.
HPAC cells are resistant to TRAIL and sensitive to FasL-dependent apoptosis while MIAPaCa-2 cells are sensitive to TRAIL-dependent apoptosis and resistant to FasL-dependent apoptosis, both of which are caspase-dependent apoptosis pathways. As a result, Fas-activating antibody CH11 (Upstate) and TRAIL were used as positive controls respectively in these cell types. In HPAC cells, pre-treatment of cells with 10 pM caspase inhibitor I (zVAD-fmk) for 1 hr resulted in an inhibition of Fas-dependent necrosis while the same pre-treatment inhibited Compound 10-dependent necrosis but did not inhibit Compound 10-induced apoptosis (Fig. 9A). In MIAPaCa-2 cells, pre-treatment of cells with zVAD-fmk resulted in an inhibition of TRAIL-dependent apoptosis while the same pre-treatment inhibited Compound 10-dependent necrosis and apparently enhanced Compound 10-induced apoptosis, perhaps as a result of the cells being blocked from advancing to necrosis (Fig.
9B). These results show that a large component of the apoptotic effect induced by Compound 10 uses caspase-independent pathways in pancreatic cancer cells while the Compound 10-induced necrotic pathways are caspase-dependent.
Caspase activation, apoptosis and necrosis were measured simultaneously in untreated and Compound 10-treated pancreatic cancer cells by flow cytometry. After 48 hrs, Compound 10 activated caspase 2, 3 and 9 in MIAPaCa-2 and PANC-1 cells (Fig. 10). Caspase positive cells were also Annexin-V-Cy5 positive showing that the Compound 10-induced caspase activation was in cells undergoing apoptosis. Approximately 60% of Compound 10-treated, caspase positive cells were Annexin-V positive and sytox blue negative indicating that they were in the early stages of apoptosis.
Approximately 30% of the caspase positive cells bound both Annexin-V-Cy5 and sytox blue indicating that these cells were entering the later stages of aspoptosis. Less than 5% of the Compound 10-induced, caspase positive cells were sytox blue positive and Annexin-V negative indicating that caspases contibute little to Compound 10-dependent necrosis.
With the exception of caspase-3 which was modestly induced in treated HPAC cells, neither caspase 2 or caspase 9 were induced in this cell line using the conditions employed (Fig. 10). At a higher concentration, (30 pM) Compound 10 activated caspase 9 but not caspase 2 in HPAC cells (data not shown). These data suggest that caspase-independent mechanisms of apoptosis are activated in Compound 10 treated HPAC cells.
Western blot analysis showed that full-length Caspase 2 (48Kd) was cleaved in MIAPaCa-2 cells by exposure to 10 pM Compound 10 (Fig. 11A). In contrast, Caspase 2 was cleaved to a lesser extent by Compound 10 in HPAC cells (Fig. 11A). Over the course of the time-course experiment, Compound 10 induced an initial drop in cleaved caspase 9(17kd) followed by an increase after 16 hr in both cell types (Fig. 11 B). Treatment with Compound 10 did not cause significant cleavage of Caspase 3 in MIAPaCa-2 and HPAC cells. Longer exposure of the same blots showed minor cleavage of Caspase 3 in HPAC but not in MIAPaCa-2 cells (data not shown).
Taken together, these experiments suggest that Compound 10 is affecting both caspase activation and synthesis.
Example 6 - Effect of Compound 10 and on in vitro mitochondrial potential and cell cycle progression In all cell lines tested (see Example 5), Compound 10 depolarized the mitochondria of these cells in a dose-dependent manner following 48 hrs of treatment showing that the intrinsic pathway of apoptosis has been activated (Fig 12).
In all three cell lines Compound 10 arrested the cell cycle in G2/M phase to varying degrees, with a loss of Go/Gi and an increase in sub-Go/Gi phase (Fig 13). The timing of Compound 10 induced G2/M arrest was different for each cell line. PANC-1 was arrested in G2/M some 4-24 hr post Compound 10 treatment and remained in arrest for at least 48 hrs. MIAPaCa-2 cells entered G2/M
arrest some 24-48 hr post Compound 10 treatment. Accompanying the arrest was a corresponding decrease in the Go/Gi cell population. The G2/M arrest observed in HPAC cells in response to Compound 10 was less pronounced and was accompanied with an arrest in Go/Gi.
However, the arrest induced would appear to be transient (Fig. 13).
Previous studies on OEC cells had shown that the caspase 3 inhibitor XIAP is significantly reduced by phenoxodiol and that this isoflavanoid stimulates auto-degradation of this BIRC family member 5(Alvero et al., 2006). In both HPAC and MIAPaCa-2 cells, Compound 10 reduced the level of XIAP
(Fig 1 1A), however XIAP degradation was more pronounced in MIAPaCa-2 cells.
Reduction of XIAP
is likely to remove a block on caspase 3 activation (Deveraux et al. 1997).
Importantly, total Akt is also reduced at an early timepoint (4hr) suggesting that total Akt removal accompanied by XIAP
degradation are two of the earliest events in Compound 10 mechanism of action.
Reduction in Akt expression would also impact on the expression of XIAP (Alvero et al., 2006 and Alvero et al., 2008).
Example 7- Effect of Compound 10 on Bc12 family member stoichiometry As noted in Example 6, Compound 10 induced mitochondrial depolarization. The inventors therefore investigated whether its action may be involved in altering the stoichiometry of pro-apoptotic (Bid, Bak, Bax) and anti-apoptotic (Bc12, BcIxL) Bc12 family members. Levels of Bc12 were lowered by Compound 10 treatment in MIAPaCa-2 and HPAC cells (Fig. 11A). Treatment with either Compound 10 induced Bid cleavage over time in MIAPaCa-2 cells (Fig 11A) while there appeared to be a transitory increase in Bid cleavage by Compound 10 in HPAC cells (Fig.11A).
The cell cycle is controlled by cyclin-dependent kinases, which in turn are regulated by p21, usually in a p53-dependent pathway. Most pancreatic cancers have mutant p53, which arrests p53-dependent transcription. HPAC cells are unusual in having a wild type p53, while MIAPaCa-2 and PANC-1 have R248W and R273H mutations in p53. These mutations are in loop 3 of p53 and affect the ability of p53 to bind DNA. The basal level of p53 protein is 94x higher in MIAPaCa-2 cells than HPAC cells (data not shown). Expression of p53 in MIAPaCa-2 cells was unaffected by Compound 10 (Fig. 1113) but was elevated by 48 hr in HPAC cells (Fig.11B). p21 is vanishingly low in MIAPaCa-2 cells and is elevated by Compound 10 (Fig. 11 B), while p21 is abundant in HPAC cells and is essentially unchanged by Compound 10 (Fig. 11 B).
Example 8-Anti-tumor activity of Compound 10 alone and in combination with gemcitabine For xenograft studies, five week old male Balb/c nude mice were maintained on an isoflavone-free diet to remove background isoflavone levels contributed by standard feed. On the day of inoculation a suspension of MIAPaCa2 or HPAC cells was prepared in DMEM (-FBS), chilled on ice and then an equal volume of matrigel (BD) was added. Mice were inoculated subcutaneously with 3 x 106 MIAPaCa2 or HPAC cells bilaterally (midway between the axillary and inguinal region) along the dorsal surface, ensuring that cells to be injected were growing at mid-end log phase. Tumor growth was monitored over 10-15 days. Compound 10 was given orally by gavage in 1%
carboxy methyl cellulose (CMC) as a vehicle. Gemcitabine was injected intraperiponeally in PBS. In combination groups animals were first dosed with Compound 10 and then dosed with gemcitabine using the respective administration schedule, dosage and route of delivery stated.
In the HPAC model of pancreatic cancer, animals dosed with the Compound 10 and gemcitabine combination at 50 and 4 mg/kg respectively displayed significantly reduced rates of tumor proliferation and terminal tumor burden (% T/C = 38) in comparison to the respective single agent controls (data not shown). Further, those animals receiving the combination Compound 10 and gemcitabine at dosages half that of the single agent controls (25 mg/kg Compound 10 and 2 mg/kg gemcitabine) also had significantly reduced tumor proliferation kinetics and reduced terminal tumor burden (%T/C = 47.8) when compared to monotherapy controls. The effectiveness of both Compound 10:gemcitabine dosage combinations was further demonstrated by the observation that tumors on animals dosed with either combination proliferated at significantly reduced rates in a dose responsive manner when compared to the respective monotherapy controls (data not shown).
Together these data indicate that Compound 10 and gemcitabine when dosed in combination act synergistically in reducing overall tumor burden using the HPAC pancreatic cancer tumor model.
In the MIAPaCa-2 model of pancreatic cancer, when compared to vehicle control, orally administered Compound 10 (100 mg/kg, qdX12) retarded the rate of tumor proliferation, at a level similar to that of gemcitabine (20 mg/kg, q3dx4). Animals dose dosed with both Compound 10 and gemcitabine at 100 and 20 mg/kg respectively had significantly reduced tumor growth and terminal tumor burden (%T/C = 51) when compared to vehicle and single agent controls.
The observed mean terminal tumor burden for the combination was markedly below that of the respective single agent controls (100 mg/kg Compound 10, T/C = 94%; for 20 mg/kg gemcitabine, T/C =
79%. These data suggest that when dosed in combination, Compound 10 and gemcitabine may act synergistically to reduce overall tumor burden using the MIAPaCa-2 pancreatic cancer xenografts.
In those animals receiving high and low dose combinations of gemcitabine and Compound 10, all markers of renal and hepatic function were comparable to that of control animals as were white blood cell and red blood cell counts (data not shown). Histopathological analysis of vital organs revealed no abnormalities that could be attributed to drug toxicity (not shown). These data demonstrate that Compound 10 does not exacerbate gemcitabine toxicity with respect to the parameters measured and can be used safely in combination with gemcitabine at the dosages employed.
References Ahn E-Y, et al., Am J. Pathol. 2003 163: 2053-2063.
Alvero AB, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells, Cancer2006 Feb 1; 106 (3): 599-608.
Alvero AB, et al. Anti-tumour activity of phenoxodiol: From bench to Clinic.
Future Oncology 2008 (accepted).
Behrens BC, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987 Jan 15; 47 (2):
414-418.
Deveraux QL, et aI. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997 388: 300-304.
Hail Jr N, et al. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis 2006;11: 889-904.
Hay N and Sonenberg N. Upstream and downstream of mTOR. Joumal Genes & Dev 2004; 18:
1926-1945.
Kamsteeg M, et al. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003 May 1; 22 (17): 2611-2620.
Kelly MG, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006 Apr 1; 66 (7): 3859-3868.
Kluger HM, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007; 5: 6.
Seglen P0 and Bohley P. Autophagy and other vacuolar protein degradation mechanisms.
Experientia 1992 Feb 15; 48 (2):158-172.
Seglen P0 and Bohley P. Autophagy and other vacuolar protein degradation mechanisms.
Experientia 1992 Feb 15; 48 (2):158-172.
Claims (28)
1. A method for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) wherein R1 is hydrogen, hydroxy, alkyl, alkoxy, halo or OC(O)R7, R2 and R3 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, halo or OC(O)R7, R4, R5 and R6 are independently hydrogen, hydroxy, alkoxy, alkyl, cycloalkyl, acyl, amino, C1-4-alkylamino or di(C1-4-alkyl)amino, OC(O)R7 or OR8, R7 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl or amino, and R8 is aryl or arylalkyl, R9 and R10 are independently hydrogen, hydroxy, alkyl, alkoxy or halo, and the drawing "~" represents a single bond or a double bond, or a pharmaceutically acceptable salt or derivative thereof.
2. The method of claim 1 where exposure of the cell to the compound occurs ex vivo or in vitro.
3. The method of claim 1 or 2 wherein the cell is not a cancer cell.
4. The method of any one of claims 1 to 3 wherein the cell is selected from a myocardial cell or an immune cell.
5. The method of any one of claims 1 to 4 wherein the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
6. The method of any one of claims 1 to 4 wherein the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
7. A method for inhibiting mTOR activity in a cell, the method comprising exposing to the cell an effective amount of a compound of formula (I) as described herein.
8. The method of claim 7 where exposure of the cell to the compound occurs ex vivo or in vitro.
9. The method of claim 7 or 8 wherein the inhibition of mTOR activity comprises dephosphorylation of mTOR.
10. Use of a compound of formula (I) as described herein for inducing or promoting caspase-independent apoptosis and/or inhibiting mTOR activity in a cell.
11. Use of a compound of formula (I) as described herein for the manufacture of a medicament for treating or preventing a disease or condition, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.
12. Use of a compound of formula (I) as described herein for the manufacture of a medicament for treating or preventing a disease or condition, wherein the compound inhibits mTOR activity in at least one cell of the subject.
13. The use of claim 11 or 12 wherein the cell is not a cancer cell.
14. The use of any one of claims 11 to 13 wherein the disease or condition is associated with aberrant or otherwise unwanted cell growth or proliferation.
15. The use of claim 14 wherein the disease or condition is selected from stenosis, restenosis, transplant rejection or rheumatoid arthritis.
16. The use of claim 15 wherein for the treatment of stenosis or restenosis the compound or a composition comprising the compound is coated onto or otherwise incorporated into a stent for introduction into a coronary artery.
17. The use of claim 16 wherein the stent is such that the compound or composition is eluted from the stent over a period of time so as to achieve the desired outcome.
18. The use of claim 14 wherein the cell is a proliferating T cell.
19. The use of claim 18 wherein the disease or condition is selected from a T
cell leukemia, an autoimmune disease, and a transplant or graft rejection.
cell leukemia, an autoimmune disease, and a transplant or graft rejection.
20. The use of claim 19 wherein the autoimmune disease is selected from cirrhosis, psoriasis, lupus, rheumatoid arthritis, Addison's disease, infectious mononucleosis, Sézary's syndrome and Epstein-Barr virus infection.
21. The use of any one of claims 11 to 20 wherein the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol, with the structure:
22. The use of any one of claims 11 to 20 wherein the compound is 3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol, with the structure:
23. An agent for the treatment or prevention of a disease or condition associated with aberrant or otherwise unwanted cell growth and/or proliferation, the agent comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt or derivative thereof.
24. An implantable medical device for delivering at least one active agent to a cell or tissue in a subject, wherein the at least one active agent comprises a compound of formula (I) as described herein.
25. The medical device of claim 24 wherein the compound is coated onto or otherwise incorporated into the device for administration of the compound to the cell or tissue.
26. The medical device of claim 24 or 25 wherein the device is a drug-eluting stent.
27. A composition when used for inducing or promoting caspase-independent apoptosis and/or inhibiting mTOR activity in a cell, the composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof, optionally in association with a carrier and/or excipient.
28. A composition when used for treating or preventing a disease or condition in a subject, the composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or derivative thereof, optionally in association with a carrier and/or excipient, wherein the compound induces or promotes caspase-independent apoptosis and/or inhibits mTOR
activity in at least one cell in the subject.
activity in at least one cell in the subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2641541 CA2641541A1 (en) | 2008-10-22 | 2008-10-22 | Methods for inducing programmed cell death |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2641541 CA2641541A1 (en) | 2008-10-22 | 2008-10-22 | Methods for inducing programmed cell death |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2641541A1 true CA2641541A1 (en) | 2010-04-22 |
Family
ID=42122677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2641541 Abandoned CA2641541A1 (en) | 2008-10-22 | 2008-10-22 | Methods for inducing programmed cell death |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2641541A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016126618A1 (en) | 2015-02-02 | 2016-08-11 | Mei Pharma, Inc. | Combination therapies |
-
2008
- 2008-10-22 CA CA 2641541 patent/CA2641541A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016126618A1 (en) | 2015-02-02 | 2016-08-11 | Mei Pharma, Inc. | Combination therapies |
EP3253208A4 (en) * | 2015-02-02 | 2018-08-15 | MEI Pharma, Inc. | Combination therapies |
US10980774B2 (en) | 2015-02-02 | 2021-04-20 | Mei Pharma, Inc. | Combination therapies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6533253B2 (en) | Encapsulated drug composition and method of using the same | |
Liu et al. | Combination therapy of doxorubicin and quercetin on multidrug-resistant breast cancer and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate/d-α-tocopheryl poly (ethylene glycol) 1000 succinate mixed micelles | |
US20130245570A1 (en) | Progesterone-containing compositions and devices | |
JP6270165B2 (en) | Compositions and devices incorporating water-insoluble therapeutic agents and methods of use thereof | |
US20070212393A1 (en) | Compositions and coatings for implantable medical devices | |
JP6101346B2 (en) | Rapamycin-40-O-cyclic hydrocarbon ester, composition and method | |
CA2597323A1 (en) | Medical devices | |
US20100130598A1 (en) | Methods for inducing programmed cell death | |
US8367659B2 (en) | Oxazinyl isoflavonoid compounds, medicaments and use | |
EP3603688A1 (en) | Limus coatings and methods of use thereof | |
AU2008230055A1 (en) | Methods for Inducing Programmed Cell Death | |
CA2641541A1 (en) | Methods for inducing programmed cell death | |
US20210106728A1 (en) | Methods and devices for reducing vascular smooth muscle cell proliferation | |
JP2013508263A (en) | Methods for inducing programmed cell death | |
US20190358369A1 (en) | Drug releasing coatings for medical devices and methods of making same | |
WO2013102842A2 (en) | Device and composition for drug release | |
KR101779132B1 (en) | Pharmaceutical composition for preventing or treating restenosis comprising extracts of Nelumbo nucifera seed | |
Zhang et al. | Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro | |
WO2023043367A2 (en) | Green tea-based nanocomplexes for eye disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20141022 |